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Chapter 1
Infections
One of the first major advances in the treatment of infections has been the 
realization that the cause of infection was something that could be transmitted from 
the decaying corpses in the teaching hospitals in Vienna to the women who gave 
birth and were assisted by students who shortly before the delivery had been 
studying these corpses. As a consequence, Ignaz Semmelweis was able to greatly 
reduce the mortality from childbed fever by simply introducing some elementary 
hygienic measures1.
Another major step forward has been the introduction of antibiotics which enabled 
actual treatment if infection prevention had failed. The development of more potent 
antibiotics has reduced mortality from infections enormously. However, despite these 
antibiotics patients still die from infections and it has become increasingly clear that 
not only the infecting organism itself but also the - defense - reaction of the host 
plays a role in the outcome2.
Through the release of substances like lipopolysaccharide (LPS, also called 
endotoxin), enterotoxins, and probably others, micro-organisms induce a response in 
the infected host, resulting in the production of humoral factors which act as 
signalling proteins. These factors, which are called cytokines, have several functions 
including the physiological role to orchestrate the immunological response to the 
infection. They may exhibit either pro- or anti-inflammatory properties. A prominent 
feature of pro-inflammatory cytokines is their capacity to initiate an inflammatory 
response which results in the activation of the innate immune system, the 
coagulation and fibrinolytic pathways and a number of vasoactive compounds. End 
products of the inflammatory response are, amongst others, reactive oxygen and 
reactive nitrogen intermediates which show a powerful capacity to damage invading 
micro-organisms but also host tissues as an unwanted side effect. Examples of pro- 
inflammatory cytokines are interleukin-1 (IL-1), IL-6, tumor necrosis factor (TNF), and 
IL-8. Counterregulatory mechanisms are also present within the cytokine network 
and represented by anti-inflammatory cytokines or factors that directly neutralise the 
activity of pro-inflammatory cytokines. Anti-inflammatory cytokines are IL-2, IL-10 
and neutralising factors include soluble receptors of the pro-inflammatory cytokines 
or proteins that compete for binding to the receptor on the taget cells such as IL-1 
receptor antagonist (IL-1 ra).
T um or  necrosis  factor  and  interleukin -6
One of the first cytokines to be discovered was tumor necrosis factor, previously also 
called cachectin. At the end of the 19th century Coley observed an occasional 
spontaneous reduction of tumor mass in cancer patients who developed a serious 
infection3,4,5. The mediator which was subsequently isolated and thought to be 
responsible for this phenomenon was therefore called tumor necrosis factor-a 
(TNF)6. Efforts to elicit a similar response by administration of killed bacteria to these 
patients yielded inconsistent results, which did not make such therapy very popular7. 
Later on the pathophysiology of cachexia, often seen in parasitic infections, was 
investigated in animal experiments. The mediator which was held responsible for the
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cachexia could be induced by LPS8. Even healthy mice developed cachexia when 
given this mediator9, which was named cachectin and subsequently proven to be the 
same protein as TNF10.
TNF is produced by a variety of cells but mainly by monocytes and macrophages11. 
The strongest inducer of TNF is endotoxin/LPS. The role of TNF and its patterns of 
production have been studied in both in-vitro and in-vivo models12,13,14'15. The 
biological effects of TNF are not limited to the induction of cachexia and tumor 
cytotoxicity. TNF has many immunomodulatory effects. It acts as an endogenous 
pyrogen, induces the release of other cytokines like IL-6 and activates 
macrophages16.
IL-6 is a cytokine that was discovered almost simultaneously by different research 
groups. As a consequence, it has been given many names reflecting its biological 
activity, such as interferon-P2. B-cell stimulatory factor, hybridoma/plasmacytoma 
growth factor and hepatocyte stimulating factor17. The fact that it acts as a growth 
stimulator for B-cell hybridoma lines enables us to measure concentrations of 
biologically active IL-6. B-cells are stimulated by IL-6 to produce immunoglobulins 
and T-cells are activated. Hepatocytes increase their production of acute phase
1 ft 1Q 20proteins in the presence of IL-6 ’ and the cytokine stimulates hematopoiesis . 
After stimulation with TNF, IL-1 or LPS, IL-6 is produced by a variety of cells, most 
predominantly by monocytes, macrophages and endothelial cells17. If endotoxin is 
administered to healthy volunteers, circulating IL-6 becomes detectable after ± 45 
minutes and reaches its maximum after approximately 2 hours21.
Effect of  bacteria  and  antibio tic  treatm ent  on the  h o st-response
During the normal course of an infection bacteria are killed by the effector 
mechanisms of the immune system; in addition, administration of antibiotics results 
in bacterial killing. Components of the bacterial cell wall can induce the production of 
cytokines such as IL-6 and TNF, not only while part of the intact micro-organism but 
also in soluble form once the bacteria have lost their structure. As a consequence, 
the clinical condition of patients that are treated with antibiotics sometimes detoriates 
shortly after the start of treatment. A well-known example of such a phenomenon is 
the Jarisch-Herxheimer reaction22 where fever and other inflammatory reactions like 
tachycardia and hypotension occur when penicillin therapy is initiated for secondary 
syphilis. Evidence that TNF is involved is found in the fact that anti-TNF infusion 
before antibiotic administration can prevent this reaction23. The explanation is that 
the destruction of bacteria by the antibiotic causes the release of (more) potent 
inducers of inflammatory cytokines. This was confirmed by in vitro studies on the 
release of LPS by antibiotic-killed gram-negative bacteria which was shown to be 
dependent on both the concentration and the type of antibiotic22,24. LPS release 
subsequently resulted in an increased induction of cytokines25,26. The capacity to 
induce cytokines depends on the composition of the bacterial cell wall. Not only LPS 
of gram-negative bacteria but also lipoteichoic acid and peptidoglycan which are cell 
wall fragments of gram-positive bacteria show cytokine-inducing activity27.
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It should be emphasized that the results mentioned above do not constitute a 
justification for withholding antibiotics from the infectious patient: no treatment might 
lead to more endotoxin release than treatment, as demonstrated in the case of N. 
meningitides infection28.
Antibiotics themselve seem to have an immunomodulatory effect too. Polymyxin B is 
well known as a potent inactivator of LPS29. Evidence that other mechanisms than 
inactivation of LPS are involved in the inactivating effects of some antibiotics comes 
from studies where not only LPS was used but also bacteria30. Another study where 
Gram-positive bacteria were used showed also an inhibitory effect of erythromycin31.
TNF AND IL-6 IN PATHOLOGY
TNF: TNF is thought to play a pivotal role in the cytokine cascade which is induced 
as a result of serious infections or polytrauma and ultimately may result in the 
multiple organ dysfunction syndrome (MODS)32,33,34. Supporting evidence is found in 
experimental studies on MODS, where specific patterns of TNF production have 
been demonstrated during the progression of disease35. Also, in patient studies 
circulating levels of TNF have been shown to correlate with both the severity and 
outcome of disease (Table 1). Although it appears that in most studies such a 
relation has clearly been established, it should be noted that this is not always the 
case.
Table 1: Correlation between plasma TNF concentrations and disease 
severity/outcome
Positive correlation
Reference Patientgroup Type of correlation
Kern91
Damas92
Waage93
Casey94
Tang95
Függer96
Malaria patients
Severe sepsis patients
Patients with meningococ septic shock
Patients with sepsis
Surgery for intra-abdominal infection
Patients with intra-abdominal infection
severity: outcome 
severity: outcome 
severity; outcome 
severity; outcome 
post-operative condition 
severity
No correlation
Reference Patientgroup Remarks
Deuren97
Beaux98
Liaw99
Papini100
Meningococcal infections 
Patients with acute pancreatitis 
Patients with septic shock 
Burnwound surgery or dressing
below detection limit 
not elevated 
survival/APACHE III 
no significant increase
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Additional support for the central role of TNF in the deleterious response to infection 
or trauma is found in experimental studies which have employed anti-TNF antibodies 
to improve outcome in various disease models (Table 2). Similar efforts to block TNF 
effects by administration of antibodies or soluble TNF-receptor have also been 
performed in patients (Table 3). Although some benefit has been reported, the 
results from larger trials have been largely disappointing.
Table 2 : Anti- TNF treatment for inflammatory disease in animal models
Inflammatory condition Model Outcome Reference
Gram-negative shock Mice Improved Silva101
bowel ischemia Rats Improved Squadrito102
in vivo/vitro endotoxin model Mice Low IL-6 response Engelberts15
endotoxic shock Baboons Improved Emerson103
shock/resuscitation model Mice Lower cytokine release Abraham104
No effect on lung injury
p55 knockout mice with LPS Mice Resistance to LPS Dounib105
MODS-syndrome Mice Improved Jansen106
Table 3: Outcome of human trials with anti-TNF treatment for inflammatory disease
Disease Treatment_____ Efficacy Reference
Septic shock 
Sepsis
Cerebral malaria 
Severe sepsis 
Severe sepsis 
Septic shock
sTNF-R
anti-TNF
anti-TNF
anti-TNF
sTNF-R (p55)
anti-TNF
no improvement of mortality0 
no improvement of mortality10 
attenuation of fever 
no improvement of mortality 
trend to improved mortality 
no improvement of mortality
.107Fisher
Cohen
Kwiatkowski
108
109
,110Fisher 
Abraham 
Abraham
in
112
0 Higher mortality at higher dose 
10 Some benefit on clinical parameters
Some of the inconsistent results reported in studies into the correlation between 
circulating TNF concentrations and disease severity may be explained by differences 
in both the time of sampling and the TNF assays employed. TNF forms a complex 
with soluble TNF-receptors (see below) which is not detected by the bio-assay and 
some of the immunological assays. Moreover, delay between insult and initial blood 
sampling may result in underestimation of TNF levels because of its short plasma 
half-life. Another important point is that circulating concentrations may not represent 
the actual situation in the tissues, where paracrine release of cytokines actually 
occurs. Finally, the genetic background of the patients may be an important
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denominator in the response to infection and the final clinical outcome. The 
polymorphism of the TNF promotor-gene region might be an indicator for such a 
predisposition. Two different alleles, TNFA1 and TNFA2, have been identified within 
the TNF gene promotor region. The presence of TNFA2 reportedly predisposes for 
more severe malarial disease and worse outcome36. A similar correlation between 
TNFA2 and disease severity and outcome was found for patients with 
meningococcal disease37. In severe sepsis, a correlation was found between the 
circulating concentration of TNF and the expression of TNFB1 and TNFB2 alleles, 
which also belong to the TNF locus38. Patients who were homozygous for TNFB2 
exhibited significantly higher concentrations of TNF than those who were 
heterozygous or homozygous for TNFB1. Targeting anti-TNF strategies to patients
39with a specific genetic predisposition might improve outcome .
Table 4: Correlation between plasma IL-6 concentrations and disease 
severity/outcome
Positive correlation
Reference Patientgroup Type of correlation
Damas92 sepsis severity; outcome
Waage93 meningococcal septic shock outcome
Hack113 sepsis outcome
Deuren97 meningococcal infections severity; outcome
Casey94 sepsis outcome
Függer96 intra-abdominal infection severity
Steinmetz114 granulocytopenic cancer indicator of sepsis; outcome
Lehrnbecher115 neonates at risk for sepsis indicator of sepsis
Beaux98 pancreatitis severity
Liaw99 septic shock outcome
Bencosme116 sepsis outcome
Papini117 burnwound surgery/dressing size of burns; outcome
Bhutta118 typhoidal salmonellosis severity; failure of treatment
Martin119 septic shock/multiple trauma sepsis: outcome
trauma: indicator of infection
No correlation
Reference Patientgroup Remarks
Rusconi120 meningococcal infections levels at admission no relation
with severity or outcome
IL-6: In patients with sepsis syndrome, IL-6 mostly correlates with disease severity 
and/or outcome (Table 4). With a few exceptions, a relation between circulating IL-6 
and disease severity or outcome has been found. Moreover, any correlation appears 
to be stronger and more consistent for IL-6 than for TNF. However, this does not
13
Introduction
mean that IL-6 itself is responsible for the lesser outcome. Anti-IL-6 antibodies have 
been applied in experimentally induced sepsis. While one study reports a beneficial 
effect of such therapy40 another study showed only marginal improvement although 
sufficient blocking was achieved41. Another way of investigating the role of IL-6 is by 
using IL-6-deficient mice. Injection of LPS in IL-6-deficient mice leads to the same 
clinical response as in wild-type mice. However, the circulating concentration of TNF 
was much higher in the IL-6-deficient mice42. This indicates that either a 
compensatory increase of TNF is generated or that IL-6 has a downregulating effect 
on TNF concentrations. Likewise, IL-6-deficient mice show a response to TNF 
injection43 which is similar to the response in wild-type mice.
Thus, other (counter-)regulating mechanisms must play a role in the final effects of 
TNF and IL-6 since administration of the specific antibodies did not result in 
improvement of disease outcome in a number of cases. Possibly, the explanation 
may be found in the functional role of the circulating receptors for TNF and IL-6.
R ecepto rs  f o r  TNF and IL-6
In order to induce any effect, cytokines have to bind to their respective receptors. 
These receptors are not only found on the outer membrane of the effector cells but, 
for some cytokines, also in a soluble form in body fluids. Such receptors have been 
characterized for both TNF and IL-6.
TNF-receptors: Two TNF-receptors can be distinguished, the p55 or TNF-R1 and the 
p75 or TNF-R2. Different cell types express distinct types of the TNF-receptor44 
which seem to mediate different cellular responses. The p55 appears to be involved 
in the lethal/cytotoxic effects of TNF since blocking the p55 receptor improves 
survival after LPS injection while p75 blockade does not affect outcome but appears 
to play a role in TNF-induced skin necrosis45. This has been confirmed in studies 
with p55- and p75-deficient mice, where only the p55-deficient mice showed 
improved survival after LPS injection. Surprisingly, the circulating TNF concentrations 
were significantly higher in the p75-deficient mice46. However, infection with L. 
monocytogenes and T. gondii resulted in higher mortality rates among the p55- than 
the p75-deficient animals, indicating the crucial role of TNF in resistance to these 
infections47. The p75-receptor is thought to be involved not only in the LPS- or TNF- 
induced skin necrosis but also to function as a potentiator of TNF-activity. The p75- 
receptor binds TNF with a high affinity and passes the ligand to the p55 receptor. 
Another possibility is that an internal facilitation of signalling through the p55 receptor 
is generated at a cytoplasmic level48. In addition, p75 could function as the receptor 
for membrane-associated TNF. The latter form reportedly is even more biologically 
active than soluble TNF49.
Soluble forms of both TNF-receptors can be found in biological fluids. Engelmann 
discovered in urine a protein, wich was able to block the biological activity of TNF50 
and was subsequently identified as the soluble form of the TNF-receptor51. Both 
receptors are also present in serum: under normal conditions the p55 at levels of 
approximately 1.0 ng/ml and the p75 at 1.5 ng/ml52. These concentrations can be 
affected by a multitude of factors and diseases. Levels are increased by cytokines as
14
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TNF, interferon-a53, IL-154' 551 56 and IL-257. In human monocytes TNF and IL-1 are 
able to induce shedding of the p75 receptor only56. In sepsis or experimental 
endotoxemia both p55 and p75 concentrations are elevated52,57. The same goes for 
HIV-positive patients59 and for patients with chronic renal failure60. In malaria patients 
a correlation has been described between disease severity and soluble TNF-receptor 
levels61. In meningococcal sepsis patients who showed a relatively high TNF/soluble 
receptor ratio were more prone to die than those who exhibited a low ratio62. The 
soluble TNF-receptors thus appear to have rather contrary biological effects: if bound 
to TNF they both block its biological effects and at the same time this binding 
prevents the elimination of TNF from the circulation63, thereby prolonging its half-life. 
The blocking effect has been demonstrated in experimental studies64,65. However, a 
clinical trial in patients with septic shock failed to reduce mortality.
Regarding the ability of the soluble TNF-receptors to block the biological effects of 
TNF, the p55 and p75 receptors seem to differ also. In vitro studies showed that the 
soluble p55 receptor was the best antagonist for TNF66.
The notion that soluble TNF-receptors are probably produced by proteolytic cleavage 
of the membrane TNF-receptors67 is confirmed by the finding that certain 
metalloproteinase inhibitors also inhibit shedding of TNF-receptors68.
| :  IL -6
ri:gp80
f l : g p 130
Figure 1: Signal transduction by IL-6 via the membrane-bound IL-6 receptor.
IL-6 binds to the ligand binding site of the gp80 subunit (1) of the IL-6 receptor. 
Subsequently, this complex (2) binds to to the gp130 subunit forming a high-affinity binding 
complex for IL-6. and a signal is generated within the cell (3).
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IL-6 receptors: The IL-6 receptor is expressed on the surface of cells that are 
responsive to IL-6 and consists of two subunits. A ligand-binding site with a 
molecular weight of approximately 80 kDa (gp80) and a separate signal-transducing 
component of approximately 130 kDa (gp130)69. IL-6 binds to the low-affinity ligand- 
binding site gp80 and the complex subsequently complexes with the signal- 
transducing protein leading to a high-affinity binding of IL-6 and a biological response 
of the cell70,71 (Figure 1). The gp130 subunit may also act as the signal-transducing 
protein for other cytokines. Oncostatin M, Leukemia inhibitory factor (LIF) and ciliary 
neurotrophic factor (CNTF) also bind to their respective ligand-binding sites and 
subsequently generate a signal via gp13072.
Soluble forms of both the gp80 and gp130 subunits can be found in different 
biological fluids. The soluble form of gp80, slL-6R, was found in urine by Novick in 
198973 and thereafter in human serum by the group of Kishimoto74. Cell lines 
expressing the IL-6-receptor are able to generate slL-6R in the medium. This can 
either be done by shedding of the extracellular part of gp80 into the medium75 or 
through alternative splicing of the mRNA for gp8076. Human T-cells appear to be 
able to produce slL-6R by both mechanisms77. The cytokine oncostatin M 
upregulates and IL-1 and IL-6 itself downregulate the expression of gp80 but it is 
unknown whether this also leads to a changed production of slL-6R78,79. The gp130 
subunit can also be found in the supernatants of cells expressing this signal 
transducing part of the IL-6-receptor80 and in human plasma81. Its production does 
not seem to depend on alternative splicing of the mRNA82.
The functional properties of the slL-6R are different from those of the soluble TNF- 
receptors. Where the soluble TNF-receptors inhibit the biological activity of TNF, sIL- 
6R enhances the biological activity of IL-6. This has been demonstrated in vitro 
where B9 cells, which depend on IL-6 for their growth, show an increased response 
to IL-6 in the presence of slL-6R83. In addition, the IL-6 induced acute phase protein 
production by a hepatocytic cell line is enhanced in the presence of SIL-6R84. This 
biological activity of slL-6R was confirmed in vivo in rats which showed an enhanced 
and prolonged response to IL-6 if it was administered intracerebroventricularly 
together with slL-6R85. A complex of IL-6 and slL-6R can still associate with the 
membrane-bound gp130 and induce signal-transduction (Figure 2). Thus, the 
transmembrane part of gp80 is not essential for signal-transduction. In contrast to 
the soluble gp80, the soluble gp130 can inhibit the biological action of IL-681, 
probably by binding to the complex of IL-6 and slL-6R. These opposite roles of both 
soluble receptor units have been confirmed by the finding that slL-6R can act as a 
growth factor in Kaposi sarcoma cells which almost completely lack membrane- 
bound IL-6R. The growth stimulation is then inhibited by the addition of soluble 
gp13086.
The results described above imply that data from studies on circulating cytokines will 
be difficult to interpret if the soluble receptors are not measured at the same time. 
The balance between the cytokine and its soluble receptor will ultimately determine 
its physiological effect. Several studies have investigated the concentrations of sIL- 
6R in different diseases often known to be associated with an increased presence of
16
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IL-6. For instance, patients with multiple myeloma show enhanced circulating IL-6 
levels, especially so during a phase characterized by proliferation of the plasma 
cells. These patients also have increased serum slL-6R levels87. Patients with HTLV-
1 infection showed increased concentrations of circulating gp130, correlating with 
disease severity88. The slL-6R level might even be used as a diagnostic marker. 
Bone marrow transplant patients who develop graft versus host disease show an 
increase in sll_-6R concentrations89 and patients with inflammatory bowel disease 
had higher levels of slL-6R in the acute phase than in an inactive phase of the 
disease90.
IL-6
gp80
gp130
Figure 2: Signal induction by IL-6 via soluble IL-6 receptor.
IL-6 binds to the ligand binding site of the soluble form of gp80 (1). Subsequently this 
complex (2) binds to to the gp130 subunit forming a high affinity binding complex for IL-6. A 
signal is generated into the cell (3).
A im  of  th e  studies
Both TNF and IL-6 are important markers for and, to some extent, mediators in 
severe infections. The aim of this study was to delineate the clinical significance of 
slL-6R in severe bacterial infections. At the start of our studies data were only 
available on soluble TNF-receptors in clinical disease. In this thesis clinical and 
experimental studies are described which focus on both these cytokine receptors.
For IL-6, TNF- and the soluble TNF-receptors p55 and p75 assays were available 
and reference concentrations in different human body fluids had been described.
17
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This was not the case for the slL-6R. The development of an assay for the 
measurement of slL-6R was therefore the first objective. The assay had to be 
optimised for the measurement of reference values for slL-6R in different body fluids 
(chapter 2). The data obtained values were used the comparison with slL-6R 
concentration in pathological situations.
Studies on soluble TNF-receptors had indicated a significant influence of the renal 
function on the circulating concentrations. This had been shown in patients with 
chronic renal failure and also in sepsis-patients with or without renal failure. Renal 
failure is often a complicating factor in severe infections. We therefore studied 
whether the slL-6R was affected in a similar way as the sTNF-R. For this purpose, 
the concentrations of sll_-6R gp80 and gp130, for which an assay had also become 
available, were measured in patients with different degrees of chronic renal failure. 
Since one could speculate that renal replacement therapy would influence the 
concentrations, blood was also analyzed at different time points before and after 
dialysis (chapter 3).
We were also interested in the situation where the patient suffered an acute illness 
with concomitantly high levels of circulating cytokines. Such a disease is the sepsis- 
syndrome. As mentioned before, high concentrations of TNF- and IL-6 are found, 
especially in the acute phase of the disease. IL-6 concentrations in the acute phase 
show a correlation with disease severity and outcome. In order to investigate if this 
would also be true for its soluble receptor gp80 we studied the patterns of slL-6R in 
these patients during the acute phase of sepsis (chapter 4).
Another disease with is characterized by very high concentrations of circulating IL-6 
is meningococcal infection. For the purpose of investigating the relation between sIL- 
6R and IL-6, we compared their patterns in the circulation during both the acute 
phase of the disease (characterized by high IL-6 concentrations) and the recovery 
phase (when IL-6 concentrations normalize). In some of these patients plasma or 
whole blood exchange is performed in order to accelerate the removal of endotoxin. 
We examined the effect of this therapy on the IL-6 and slL-6R concentrations 
(chapter 5).
Functionally, the slL-6R acts completely different from the soluble TNF-receptors. 
Circulating levels of the latter are low under normal conditions and increase under 
conditions where TNF is produced. For slL-6R this situation seems to be reversed. 
The soluble TNF-receptors act as antagonists where the slL-6R is an agonist. In the 
same group of patients with meningococcal infections the patterns of the soluble 
TNF-receptors were studied in comparison to those of the SIL-6R. The effect of 
plasma and whole blood exchange on the soluble TNF receptor concentrations were 
also studied (chapter 6).
18
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Highly similar bacteria may induce diseases of very different degrees of severity. 
One of the reasons for these differences might be found in the potential of the 
bacteria to induce cytokines and their receptors. This had already been studied to 
some extent in cell cultures. One could argue that a whole blood system would 
provide a more natural environment to examine the inducibility of cytokines by 
bacteria. Since soluble receptors proved not to be produced in whole blood after 
bacterial stimulation, we investigated the production of various cytokines by a 
number of bacteria with different potential to induce diseases with different grades of 
severity. We also studied the effect of antibiotic treatment, since it could be 
speculated that antibiotics alter the cytokine-inducing capacity by changing relevant 
structures within the bacterial membrane (chapter 7).
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SIL-6R in biological fluids
A bstract
Objective.
Measurement of baseline soluble interleukin-6 receptor (slL-6R) and interleukin-6 (IL- 
6) levels in biological fluids in non-pathological conditions.
Subjects and materials.
Blood and urine were obtained from healthy volunteers. Cerebrospinal fluid (CSF) and 
synovial fluid (SF) were obtained from patients during spinal puncture and athroscopy, 
respectively. Only CSF and SF of patients with proven non-pathological conditions 
were used in this study. Both slL-6R and IL-6 were measured using ELISA's. It was 
shown that neither did slL-6R interfere with the IL-6 ELISA nor did IL-6 interfere in the 
slL-6R ELISA. Moreover, addition of recombinant slL-6R to the IL-6 bio-assay (B9) did 
not influence IL-6 recovery.
Results:
Using our slL-6R ELISA we found baseline levels for slL-6R in serum of 76.6 ± 19.3 
ng/ml in serum and 3.7 ± 1.3 ng/ml in urine. In non-pathological conditions slL-6R 
concentrations in CSF are 1.6 ± 0.4 ng/ml, and in SF 11.6 ± 3.3 ng/ml, while IL-6 
concentrations are below detectable ranges in these fluids.
Conclusions:
slL-6R levels are detectable in serum, urine, CSF and SF during non-pathological 
conditions. slL-6R levels in serum outrange levels in CSF, urine and SF and large 
interindividual differences in baseline concentrations for slL-6R exist.
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Introduction
IL-6 is a multifunctional cytokine produced by many activated cell types, mediating their 
various effects on several target cells. IL-6 has been reported to be involved in 
important homeostatic processes, e.g. the induction of immunoglobulin production, T 
cell differentiation, stem cell proliferation, acute phase protein production and others1. 
Plasma IL-6 levels are increased in many pathological situations and this phenomenon 
may be very relevant clinically. For instance, a positive correlation has been reported 
between IL-6 plasma concentrations and mortality in septic patients2,3 and we recently 
found a strong correlation between circulating IL-6 levels and the development of 
multiple organ failure4.
IL-6 binds to a receptor (gp80) which is present on the outer membrane of various cell 
types. The complex of IL-6 and IL-6 receptor (IL-6R) subsequently interacts with a non­
ligand binding membrane glycoprotein (gp130) resulting in signal transduction5.
A circulating soluble form of gp80 has been found in plasma and urine of healthy 
volunteers6,7. Similar soluble receptors have been found for many cytokines, e.g. IL-28, 
IL-49, IL-710, and TNF-a7,11. These soluble receptors are thought to have a neutralizing 
function: cytokines lack biological activity when bound to their soluble receptor. The 
function of these circulating soluble cytokine receptors might thus be the protection of 
the organism against excess activity of harmful cytokines. However, unlike all known 
soluble cytokine receptors, soluble IL-6R (slL-6R) appears not to exert an antagonistic 
role but, on the contrary, to enhance the response to IL-612'14. This 50-55 kDa 
glycoprotein can bind with IL-6 and the complex will associate with gp130 and induce 
its biological effects. The presence of slL-6R might therefore enhance the biological 
effect of released IL-6. In this study we investigated the presence of baseline slL-6R 
concentrations in serum, urine, CSF and SF during non-pathological conditions. The 
influence of IL-6 on the slL-6R ELISA and slL-6R on the IL-6 ELISA and bio-assay was 
also investigated.
Materials  and  methods
Recombinant soluble human IL-6R (slL-6R) and antibodies to slL-6R. These were a 
gift of Innotherapie Laboratoires Besançon, France. Coating antibody: B-N12, 
conjugate antibody: biotinilated B-R6. slL-6R (a 55 kDa glycoprotein) was isolated from 
the supernatant of a transfected COS cell line (Wijdenes: manuscript in preparation). 
ELISA forslL-6R. A flat-bottom 96 wells plate (Costar 3590 EIA/RIA plate) was coated 
with the anti-slL-6R monoclonal antibody B-N12 (1.0 ng/ml) overnight at 4°C. After 
washing three times with phosphate buffered saline (PBS), containing 0.05% (v/v) 
Tween 20 (PBS-T), the plate was incubated for 1 h at room temperature with 200 |xl 
PBS containing 5% (w/v) Bovine Serum Albumin (Sigma A.7030) in order to prevent 
aspecific binding. Subsequently, the plate was washed three times with PBS-T and 
samples (100 jal) were added to the wells. A standard titration curve was obtained from 
a serial dilution of recombinant slL-6R. After incubation for 1 h at 37°C, the plate was 
washed three times with PBS-T, 100 |il (0.05 |j,g/ml) biotinilated BR-6 in conjugate 
buffer (pH=7.4) was added to the wells and the plate was incubated for a further hour
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at room temperature. After subsequent washing with PBS-T, streptavidin horseradish 
peroxidase (4 ng/ml in conjugate buffer, 100 (¿I/well) was added, the plate was 
incubated for 45 min at room temperature and washed 5 times with PBS. Thereafter 
100 \i\ substrate (O-phenyldiamine, Sigma P6912, 0.5 mg/ml in substrate buffer 
pH=5.2) activated with H2O2 was added. After 15 min the colour reaction was 
terminated with 50 |^ l 2.5 N H2S04 and the optical density (OD) was read at 492 nm 
with a plate reader (Titertek Multiskan MCC/340).
ELISA forlL-6. The same procedure as described for the slL-6R ELISA was used, with 
BE-8 as the coating and biotinilated BE-4 as the conjugate antibody31. The standard 
titration curve was made of serial dilutions of recombinant IL-6.
IL-6 bioassay. Murine hybridoma B9 cells which are dependent on IL-6 for growth32 
were used in this assay. In a flat bottom 96 wells cell culture plate (Nunc) 100 l^ of the 
diluted test sample was added to 100 l^ cells suspended at a concentration of 5*105 
cells/ml in Iscove's Modified Dulbecco's Medium (IMDM) with 10% (v/v) heat inacti­
vated Foetal Calf Serum (FCS) and gentamicin (40 ng/ml). Serial dilution of samples 
and standards were made in IMDM containing 10% (v/v) FCS and gentamicin (40 
ng/ml). After 72 h incubation at 37°C in 5% CO2 , 0.2 jo.Ci tritiated thymidine (3H- 
thymidine) was added to each well and the plates were incubated for a further 18-24 h. 
Subsequently, cells were harvested and 3H-thymidine incorporation was measured 
(Packard, Matrix-96). One unit IL-6 is defined as the amount which induces half 
maximal incorporation of 3H-thymidine.
Determination of normal concentrations of slL-6R in blood. Venous blood was collected 
from healthy volunteers. Tubes were either centrifuged (10 min at 2000 g) immediately 
(plasma, EDTA), or allowed to clot (serum) for 1 h. Serum or plasma was separated 
from the cell-pellet and stored at -20°C until assay. In order to study possible 
interference of the anticoagulant in the slL-6R ELISA, blood was collected from six 
healthy volunteers into tubes (Monoject, Sherwood Medical) containing either citrate, 
EDTA, heparin or sodiumfluoride/potassium oxalate.
Stability of slL-6R, in plasma. Part of the plasma samples from three volunteers was 
placed for 24 h at 37°C, room temperature, or 4°C. In addition , the effect of repeated 
(up to 6 times) freeze-thawing was investigated.
Determination of normal concentrations of slL-6R in cerebrospinal fluid (CSF). CSF 
was collected from 18 persons who underwent a lumbar puncture during the diagnostic 
tests for hernia nuclei pulposi. All standard laboratory tests (e.g. leucocyte count and 
glucose level) were normal in this CSF.
Determination of normal concentrations ofslL-6R in urine. Urine was collected from 11 
healthy volunteers at random time points during the day. The urine was centrifuged 
before assay in order to remove amorfic deposits.
Determination of normal concentrations of slL-6R in synovial fluid. Synovial fluid was 
collected from the knee of 9 persons who underwent an arthroscopy. Before the 
insertion of the scope the joint was punctured and fluid collected. Subjects were either 
diagnosed as suffering from some traumatic or degenerative lesion or no diagnosis 
could be made. If macroscopic contamination of the synovial fluid with blood was 
apparent, blood cells were removed by centrifugation at high speed.
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R esults
Interference of IL-6 in the sJL-6R ELISA. Increasing amounts of IL-6 were added to the 
standard curve for the slL-6R assay. Figure 1 shows that concentrations up to 400 
U/ml did not significantly affect the response to slL-6R. Since circulating IL-6 
concentrations in patients may be much higher than 400 U/ml, we also added high 
concentrations of IL-6 to an assay buffer containing 3.1 and 12.5 ng/ml slL-6R, 
respectively. After addition of 1.2*105 U/ml IL-6, recovery of 3.1 ng/ml SIL-6R was 
102% and recovery of 12.5 ng/ml slL-6R was 105%. Addition of 105 U/ml IL-6 to serum 
of a healthy volunteer resulted in a recovery of 97% for slL-6R. All recovery 
percentages were calculated as percentage of the outcome without the addition of IL- 
6.
S IL -6R  (n g /m l)
Figure 1: Effect of rlL-6 in the slL-6R ELISA.
Concentrations are: 0 (□), 50 (O), 100 (V) and 400 (■) U/ml IL-6. Values are means from 
duplicate measurements.
Interference ofslL-6R in the IL-6 ELISA. Increasing amounts of slL-6R were added to 
known concentrations of IL-6 and the recovery of IL-6 was measured (table 1). No 
interference of slL-6R in the IL-6 ELISA was observed.
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Table 1: Recovery of IL-6 in f/je IL-6 ELISA in the presence of slL-6R. Data given are 
means ± SD from diploid determinations.
slL-6-R added 
(ng/ml)
IL-6 measured 
(U/ml)
0 <20 50 ±4 110 ± 9 394 ±4
2 <20 50 ±4 90 ±1 401 ±3
10 <20 47 ±2 92 ±5 399 ±3
50 <20 60± 11 95 ±3 406 ±15
Interference of slL-6R in the IL-6 bioassay. Increasing amounts of slL-6R were added 
to the standard curve for the IL-6 bio-assay. Figure 2 shows that only at the highest 
concentration used, 25 ng/ml, slL-6R appeared to slightly reduce 3H-thymidine 
incorporation. However, this effect remained non-significant.
1   1---------------------------------------------1---------------------------------------------1--------------------------------------------- 1--------------------------------------------- 1
0 1 2 3 4  5
IL-6 U/ml
Figure 2: Effect ofslL-6R in the B9 bio-assay.
The data (means from triplicate measurements) represent 3H-thymidine activity incorporated in 
the cells. Dashed line is the IL-6 reference line without the addition of slL-6R. Other lines 
represent the outcome in the presence of 0.4 (♦), 0.8 (□), 1.6 (0), 3.1 (V), 6.3 (O), 12.5 (A), 
and 25 (+) ng/ml slL-6R.
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Normal values for slL-6R in blood. Table 2 shows the results of corresponding serum 
and plasma samples from healthy volunteers. On average serum contained 76.6 ± 
19.3 ng/ml and plasma 73.4 ± 20.6 ng/ml slL-6R. A two-sided paired t-test showed no 
significant difference between values in serum and plasma.
In addition, plasma slL-6R levels were independent from the anticoagulant used (data 
not shown).
Stability of siL-6R in plasma. Plasma was treated in various ways before assay (table 
3). Storage at 37°C for 24 h resulted in a significant reduction of measured slL-6R. 
This loss of activity was not seen after storage at room temperature or at 4°C. Freeze- 
thawing only resulted in a reduced response if such treatment was repeated 5 times.
Table 2: Levels of slL-6R in plasma and serum of healthy volunteers. Data given are 
means ± SD from diploid determinations.
Sample
number
siL-6R in serum 
(ng/ml)
slL-6R in Dlasma 
(ng/ml)
1 53.0 ± 4.2 46.5 ± 3.5
2 63.0 ± 0.0 59.5 ±4.9
3 94.5 ±2.1 97.0 ± 4.2
4 72.0 ± 4.2 63.0 ± 0.0
5 97.0 ±4.2 106.5 ±9.2
6 45.5 ± 0.7 47.0 ± 4.2
7 66.0 ± 4.2 66.0 ± 4.2
8 63.0 ± 0.0 78.0 ±4.2
9 112.5 ±3.5 115.0 ±0.0
10 80.0 ±7.1 81.0 ±0.0
11 69.0 ± 0.0 66.0± 4.2
12 88.0 ± 0.0 78.0 ± 4.2
13 69.0 ± 0.0 62.5 ± 9.2
14 100.0 ±0.0 100.0 ±0.0
15 not done 56.0 ± 0.0
16 not done 69.0 ± 0.0
17 not done 56.0 ± 0.0
mean ± SD 76.6 ±19.3 73.4 ± 20.6
Normal values for siL-6R in CSF, urine and SF. The separate measurements are 
depicted in figure 3. The average concentration of SIL-6R in CSF was 1.6 ± 0.4 (SD, 
n=18) ng/ml. IL-6 levels, measured by ELISA, were all below the detection limit. The 
average concentration of slL-6R in urine was 3.7 ± 1.3 ng/ml (n=11). The average 
concentration of slL-6R in synovial fluid was 11.7 ± 2.5 ng/ml (n=9). IL-6 levels were all 
below the detection limit.
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Table 3: Recovery of slL-6R in plasma after several pretreatment procedures. Data 
given are means ± SD from diploid determinations.
Number of slL-6R (ng/mi)
freeze-thaw
procedures plasma 1 plasma 2 plasma 3
1 46.5 ± 3.5 59.5 ±4.9 97.0 ±4.2
2 48.8 ± 5.3 53.8 ± 5.3 110.0±0
3 38.8 ± 5.3 67.5 ± 0 123.8 ±5.3
4 45.0 ± 0 71.3 ±5.3 117.5 ±10.6
5 38.8 ± 5.3 51.3 ±5.3 85.0 ± 3.5
6 38.8 ± 5.3 52.5 ± 3.5 98.8 ±15.9
After 24 hours at:
37°C 21.011.4 44.0 ±0 69.0 ± 0
RT (±20°C) 44.0 ±0 63.0 ± 0 91.0 ±4.2
4°C 40.0 ± 5.6 59.5 ±4.9 107.5 ±3.5
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Figure 3: slL-6R levels in cerebrospinal fluid (CSF), urine and synovial fluid (SF).
34
Chapter 2
D iscussion
In order to study the presence and kinetics of slL-6R in various fluids we developed an 
ELISA for this compound, together with an ELISA for IL-6. Since no influence was 
found of either IL-6 in the slL-6R ELISA or, vice versa, of slL-6R in the IL-6 ELISA we 
assume that both ELISA's measure both the complexed and the free form of slL-6R 
and IL-6, respectively. However, binding studies are necessary to confirm that our sIL- 
6R indeed forms a complex with IL-6.
Addition of recombinant IL-6 to serum of a normal volunteer does not influence the 
measurement of native slL-6R. This is another indication that our slL-6R ELISA also 
measures the complexed form of slL-6R.
In the B9 bio-assay no effect could be detected of adding recombinant human slL-6R 
to the cell culture. It is possible that the human gp80 is unable to form a complex with 
the murine gp130 (if present at all on the B9 hybridoma cells) and therefore to induce a 
signal into the cell. All studies reported so far describing the biogical activity of soluble 
gp80 were done on human cell-lines12'14. Studies into the effect of murine slL-6R on 
the IL-6 bio-assay would be of interest because levels of IL-6 in mice are often deter­
mined by the IL-6 bio-assay.
The slL-6R serum concentrations in volunteers vary between 53 -112.5 ng/ml. These 
baseline values are similar to those reported very recently but measured by another 
assay6,13. Various anticoagulants do not influence the slL-6R ELISA. Thus, if serum is 
not available, plasma can be used instead.
In CSF baseline levels of slL-6R appear to be very low ranging, from 0.8 - 2.2 ng/ml. 
Apparently, the slL-6R does not pass the blood-brain barrier very well and the local 
production in the brain is low or absent. The IL-6 levels in CSF were all below 20 U/ml. 
In meningitis (bacterial and non-bacterial) and multiple sclerosis elevated levels of IL-6, 
and/or TNF-a, are found in CSF15,16. Very little is known about soluble cytokine 
receptors in CSF. It has been reported that levels of soluble IL-2 receptor (slL-2R) in 
CSF show a moderate increase following subarachnoid hemmorhage while in CSF 
obtained from a control group low levels (compared to serum) of slL-2R are found17. 
This observation is in accordance with the low slL-6R levels in CSF, as compared to 
serum, found in this study.
The presence of slL-6R in urine has also been described by Novick et al7. We find a 
concentration range between 1.7 and 5.6 ng/ml. This probably means that only a small 
amount of slL-6R is cleared through the kidneys. The soluble TNF receptor level found 
in urine of healthy women is relatively high concentration compared to the slL-6R con­
centration18. The serum/urine ratio is much lower for the soluble TNF receptor than for 
the slL-6R. This indicates that the soluble TNF receptor is cleared at a higher rate by 
the kidneys than slL-6R.
There are many reports on the involvement of cytokines in several types of 
arthritides19,20. Soluble TNF receptor is also found in synovial fluid (SF), and levels 
correlate with disease activity in distinct forms of arthritis21,22. The concentration 
gradient between serum and SF suggests a local production of soluble TNF receptor. 
We measure an average of 11.6 ± 3.3 ng/ml slL-6R in SF, which value is much lower
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than that in serum. Whether this is a result of local production or passage from the 
blood stream into the joint is not clear. No IL-6 could be detected in the SF samples. 
The cells and mechanisms which regulate the slL-6R production in biological fluids are 
not yet known. It can be the result of so called receptor shedding: proteolytic cleavage 
of membrane bound IL-6R23. The ligand binding site of the gp80 subunit is cleaved 
from its transmembrane part resulting in a ligand binding protein of approximately 55 
kDa. However, the presence of mRNA encoding a soluble IL-6R suggests a direct 
production of slL-6R24. Whether this is a result of direct transcription of an mRNA 
encoding for slL-6R or of alternative splicing of an mRNA encoding for the total gp80 is 
not known.
There are some data on the effects of several immunomodulators on the production of 
slL-6R or the expression of the membrane bound gp80 and gp130 by cell cultures. 
Phorbol myristate acetate enhances shedding of slL-6R from transfected COS7 cells 
and protein kinase C seems to be responsible for this shedding25. Leukemia inhibitory 
factor down-regulates the expression of high affinity IL-6R on murine myelomonocytic 
cells and the presence of IL-6R mRNA26. IL-6R R> chain expression (gp 130) is 
enhanced by IL-6, IL-1 and TNF in human epithelial cells27. Whether IL-6 also 
enhances the production of SIL-6R is not clear: Mullberg et al. report that IL-6 has no 
effect on shedding of the gp80 ligand binding protein23. In HepG2 cells dexamethason 
up-regulates IL-6-R expression. This is accompanied by an increase of acute phase 
protein production28. The main mechanisms of clearance of the slL-6R are also 
unknown.
The levels of slL-6R in the serum of healthy individuals are very high compared to 
those of the soluble TNF receptor11. In pathological conditions such as general 
inflammation11, human malaria29, rheumatic diseases22, and severe 
meningococcaemia30, soluble TNF receptor is elevated. The results of a study 
performed by us with septic patients show a decrease of slL-6R levels (Frieling et al.: 
manuscript in preparation). This means that high baseline slL-6R levels decrease and 
low baseline soluble TNF receptor levels increase in pathological situations. The 
different biological activity of soluble TNF receptor (antagonistic) and slL-6R (agonistic) 
might be the reason for this opposite reaction. However reports on HIV-seropositives6 
and patients with monoclonal gammopathy13 describe an increase of slL-6R levels. 
Investigations concerning these patients are in progress.
The clinical relevance of a certain amount of circulating slL-6R is not yet clear. It could 
play a role in IL-6 kinetics, preventing a rapid clearance of circulating IL-6 from the 
blood stream. However in pathological conditions the amount of IL-6 produced (up to 
106 pg/ml) exceeds the baseline level of slL-6R many times, thus rendering it less 
relevant for the clearance rate of IL-6.
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Soluble IL-6 receptors in chronic renal failure
A bstract
Background:
Circulating receptors will modulate the biological effects of cytokines. Renal insufficiency 
is known to influence the concentrations of the soluble tumor necrosis factor (TNF) 
receptors p55 and p75. No data are available on the concentrations of the circulating 
interleukin-6 (IL-6) receptors gp80 and gp130 during chronic renal insufficiency. 
Methods:
We compared the serum concentrations of the IL-6 receptors gp80 and gp130 to those 
of the TNF receptors p55 and p75 in end stage chronic renal failure (CRF), continuous 
ambulatory peritoneal dialysis (CAPD), and hemodialysis (HD).
Results:
In healthy controls the concentrations of gp80, gp130, p55 and p75 in serum were 82.1 
± 24.3, 87.9 ± 20.2,1.1 ± 0.2, and 1.7 ± 0.3 ng/ml, respectively. These concentrations 
were increased to, respectively, 112.2 ± 18.0, 186.0 ± 37.7, 10.5 ±4.3 and 15.0 ± 7.5 
ng/ml in CRF, 138.8 ± 18.0,181.3 ±46.1, 25.5 ± 5.2 and 19.1 ± 3.4 ng/ml in CAPD, and 
107.9 ± 29.4, 146.6 ± 30.5, 22.9 ± 6.3 and 16.8 ± 6.0 ng/ml in HD (before dialysis 
session). Concentrations after hemodialysis were higher for p75 only.
Conclusions:
The data show that the concentrations of the IL-6 receptors (gp80 and gp130) are 
elevated in chronic renal insufficiency. The increase is relatively low compared to the 
elevation of the TNF receptors in this situation. Dialysis does not result in a consistent 
change in serum concentrations of the various receptors.
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Introduction
Circulating cytokine receptors will modulate the effects of their matching cytokines. 
Studies on both cytokines and their receptors in different clinical situations are therefore 
mandatory. The receptor for interleukin-6 (IL-6) consists of two units: a ligand binding 
part (gp80) and a signal transducing part (gp130)1. Both receptors are detectable in 
plasma of healthy humans2,3. Binding of IL-6 to its soluble gp80 receptor (gp80) results 
in an increase in biological activity4,5. In contrast, binding of IL-6 to the soluble form of 
the gp130 receptor (gp130) results in a decreased biological effect of IL-63. 
Previously, we have shown that gp80 concentrations remain unaffected by mild acute 
renal failure during the multi-organ dysfunction syndrome, whereas soluble TNF 
receptors (sTNFRs) positively correlate with creatinine concentration6. A fair correlation 
between renal function and sTNFR concentrations in serum has been documented for 
patients suffering from chronic renal insufficiency7,9 and for patients suffering from acute 
renal insufficiency during the multiple organ dysfunction syndrome due to sepsis10. 
Controversial reports have been published on IL-6 concentrations during chronic renal 
failure11,13. The presence of IL-6 will affect the gp80 and/or gp130 concentrations. 
Increased IL-6 concentrations have been observed in various clinical situations of acute 
renal failure6,13,14.
In this study we measured circulating concentrations of IL-6 and its soluble receptors 
gp80 and gp130 in non-infectious patients suffering from chronic renal failure 
necessitating dialysis, and compared them to sTNFR p55 and p75 concentrations
S ubjects and  M ethods
Patients and controls. Demographic data of the patients and controls are presented in 
table 1. Serum was collected at a random timepoint during the day from patients with 
preterminal chronic renal failure (CRF) without renal replacement therapy and from 
patients on chronic ambulatory peritoneal dialysis (CAPD). In patients on hemodialysis 
(HD) a blood sample was taken immediately after puncturing the vessel for a dialyis 
session; in a subgroup (11 patients) another sample was collected prior to removal of 
the needle from the vessel after the dialysis session. All hemodialysis patients were 
treated with low flux, biocompatible polysulphone or haemophane artificial kidneys, 
which were sterilized with ethylene-oxide and only used once. Control samples were 
obtained from blood donors. Urine samples from healthy controls were taken at random 
time points during the day. All subjects gave their informed consent prior to 
investigation.
Assays. IL-6 and gp80 were determined by Enzyme Linked Immunosorbent Assays 
(ELISA) as described previously2. The lower limit of detection was 20 pg/ml for IL-6 and 
0.4 ng/ml for gp80.
The soluble gp130 receptor was measured by ELISA. Nunc microtiter 96 wells plates 
were coated overnight at 4°C with 100 |jl anti-gp130 antibody B-P415,16 in phosphate 
buffered saline (PBS) per well. Wells were emptied and then blocked with 250 pi 20% 
(w/v) sucrose at room temperature for 2 h. After washing with 0.05% Tween-20 in PBS,
100 pi gp130 standards or serum was added together with 50 pi biotinilated anti-gp130
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monoclonal antibody B-T215,16 and the plates were incubated for 2 h at 37°C . 
Thereafter, the plates were washed with 0.05% Tween-20 in PBS and incubated for 45 
min at room temperature with 100 |jl streptavidin peroxidase (Sigma S5512,1 |jg/ml in 
PBS with 1% w/v bovine serum albumin Sigma A-7906) per well. After washing with 
PBS, 100 Ml O-phenyldiamine (Sigma P-9187, 5 mg/ml) was added and after 30 min the 
colour reaction was terminated with 100 (jl H2SO4 0.5 M and the optical density at 492 
nm was measured. The detection limit of the assay was 50 pg/ml.
Table 1: Subject characteristics.
n Age*
(y)
Male/Female Creatinine clearance* 
(ml/min)
Controls 20 55.2 ± 8.2 13/7 not done
CRF 11 54 ± 10.9 7/4 14 ±5.1
HD 16 62± 11.8 9/7 2.0 ± 3.0
CAPD 9 47 ±19.9 4/5 1 ±0.9
* given are means ± SD
CRF = pre-terminal chronic renal failure without renal replacement therapy;
HD = hemodialysis;
CAPD = continuous ambulatory peritoneal dialysis.
The sTNFRs p55 and p75 were also measured by ELISA17 (gift from W. Buurman, 
Maastricht, The Netherlands). Nunc microtiter 96 wells plates were coated overnight at 
4°C with 100 |jl monoclonal anti-TNFR antibody 4C8 (p75) or 1H7 (p55) in PBS per well. 
The plates were emptied and blocked with 150 |jl PBS containing 1% (w/v) bovine 
serum albumin for 1 h at room temperature. Subsequently, the plates were washed with 
0.01% Tween-20. Standard concentrations of sTNFR p55 or p75 or serum samples 
were added to the wells (100 pi). After incubation for 2 h at room temperature the plates 
were washed again with 0.01% Tween-20 and 100 |jl biotinylated polyclonal rabbit anti- 
TNFR antibody was added. After 1 h incubation at room temperature the wells were 
washed, 100 pl/well streptavidin peroxidase (Dakopatts P397) was added and the plates 
were incubated again for 1 h at room temperature. Tetramethylbenzidine (TMB, 
Kirkegaard and Perry Labs 50-76-00 and 50-76-03 in equal amounts, 100 pl/well) was 
added after washing the plate and the colour development was terminated after 15 min 
with 1 M H 2 S O 4 , 50 pl/well. Optical density was measured at 450 nm. The detection limit 
of the p55 and p75 ELISAs was 80 pg/ml.
For all assays, intra- and interassay coefficients of variation were below 10%. 
Statistical analysis. Differences between groups were calculated using an ANOVA and 
Bonferroni post-tests. Differences between pre- and post-dialysis samples were 
evaluated with a paired t-test. Correlations were studied using the Pearson correlation 
coefficient.
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Results
Cytokine receptor concentrations in Controls, CRF, CAPD, and HD. In the control group 
soluble receptor concentrations were 82.1 ± 24.3 ng/ml for gp80, 87.9 ± 20.2 ng/ml for 
gp130, 1.1 ±0.2 ng/ml for p55 and 1.7 ± 0.3 ng/ml for p75, respectively. In the urine of 
healthy volunteers gp130 could be detected at a concentration of 1.2 ± 0.3 ng/ml and 
gp80 at 3.7 ± 1.3 ng/ml.
In all patients with renal insufficiency, the cytokine receptors were significantly elevated 
as compared to the control group (table 2). However, the soluble TNF-receptors p55 and 
p75 were approximately 10-fold increased compared to controls while the IL-6 receptors 
gp80 and gp130 were only increased up to 2-fold. Both soluble IL-6 receptors gp80 and 
gp130 were higher in CAPD (138.8 ± 18.0 and 181.3 ± 46.1 ng/ml, respectively) than 
in HD (107.9 ± 29.4 and 146.6 ± 30.5 ng/ml, respectively) but this difference was only 
significant for gp80. The sTNF receptors p55 and p75 were only slightly elevated in 
CAPD (25.5 ± 5.2 and 19.1 ± 3.4 ng/ml, respectively) if compared to HD (22.9 ± 6.3 and 
16.8 ± 6.0 ng/ml, respectively).
IL-6 was only detectable (30 pg/ml) in one sample taken before hemodialysis: in all 
other samples the IL-6 concentration was less than 20 pg/ml.
Table 2: Cytokine receptor concentrations
gp80 gp130 p55 p75
Controls 82.1 ±24.3 87.9 ± 20.2 1.1 ±0.2 1.7 ±0.3
CRF 112.2 ± 18.0 186.0 ±37.7 10.5 ±4.3 15.0 ±7.5
pre-HD 107.9 ±29.4 146.6 ± 30.5 22.9 ± 6.3 16.8 ±6.0
CAPD 138.8 ± 18.0 181.3 ± 46.1 25.5 ± 5.2 19.1 ±3.4
ANOVA p<0.0001* p<0.0001# p<0.0001@ p<0.0001$
Values (ng/ml) reperesent means ± SD. CRF = pre-terminal chronic renal failure;
HD = hemodialysis; CAPD = continuous ambulatory peritoneal dialysis.
* Bonferroni: significant for Controls vs. others and CAPD vs. HD
* Bonferroni: significant for Controls vs. others and CRF vs. HD
@ Bonferroni: significant for Controls vs. others and CRF vs. CAPD and CRF vs. HD 
$ Bonferroni: significant for Controls vs. others
Cytokine receptors before and after hemodialysis. Figure 1 shows the receptor 
concentrations before and after a hemodialysis session. No significant differences 
between pre- and post-values were found for either gp80, gp130 or p55. The p75 
concentration was marginally, but significantly (p=0.04), elevated after hemodialysis. 
Correlation between creatinine clearance or age and cytokine receptor concentration. 
As shown in figure 2, no significant correlation was found between creatinine clearance 
and soluble receptor concentrations in the CRF group. In the control group, age was not 
correlated with cytokine receptor concentrations (figure 3).
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Figure 1: Cytokine receptor concentrations before (PRE) and after (POST) hemodialysis. 
Receptor concentrations in ng/ml. Horizontal lines indicate the mean of all samples. A = gp80, 
B = gp130, C = p55, D = p75
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Figure 2: Correlation between creatinine clearance and soluble cytokine receptor 
concentration in the end-stage chronic renal failure group. A: + = gp80, •= gp130; B: T = p55, 
■ = p75.
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Figure 3: Correlation between age and cytokine receptor concentration in the control group. 
A: + = gpBO, • = gp130; B: ▼ = p55, ■ = p75.
D iscussion
This study shows that in patients with severe chronic renal impairment the serum 
concentrations of the soluble IL-6 receptora gp80 and gp130 are increased. In a 
previous study we did not find a correlation between circulating gp80 and renal function 
in septic patients6. The patients with sepsis syndrome showed high IL-6 concentrations. 
High IL-6 concentrations are associated with low gp80 concentrations6 and IL-6 
increases the clearance of gp8018. In the present study the serum IL-6 concentration 
was below 20 pg/ml in all samples except one. Therefore, IL-6 is not expected to 
influence any increase in gp80 caused by renal impairment. Conflicting data have been 
published on the presence of IL-6 in chronic renal insufficiency. Some authors report an 
increase in IL-6 concentration11,12 while others were unable to find an increase in 
patients with chronic renal failure13.
Very little is known about the kinetics of the soluble IL-6 signal transducer gp130 in 
humans. One report shows the presence of soluble gp130 in normal human serum at 
a concentration of 390 ± 72 ng/ml3. We find a concentration of 87.9 ± 20.2 ng/ml in the 
control group and this concentration doubles in the patients with severe renal 
impairment. The small amount of gp130 found in the urine of healthy controls suggests 
that renal clearance of gp130 is normally present at a very low level. The absence of 
renal clearance is therefore unlikely to be the most important cause for the observed 
increase of gp130. The kidneys might be involved in a different way in the process of 
eliminating gp130 from the circulation, e.g. by extraction and metabolizing, thereby 
causing the increase in circulating gp130 concentration during chronic renal failure. 
The p55 and p75 concentrations found by us in healthy controls are similar to those 
reported by Aderka19. In all patient groups p55 and p75 concentrations are significantly 
elevated. This rise in circulating concentrations of p55 and p75 during renal insufficiency 
is probably caused by the impaired renal function alone since clear correlations between 
the TNF receptors concentrations and renal function have been reported20. When 
comparing normal creatinine clearance (controls) with low (CRF) or almost absent
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(CAPD and HD) creatinine clearance, we indeed observe an increase in sTNFR 
concentrations indicating a direct relation between sTNFR concentration and creatinine 
clearance. This is confirmed by the observation in one patient where a sample was 
taken a few weeks after renal transplantation. Here, both p55 and p75 receptor 
concentrations were decreased, while the gp80 and gp130 concentrations were not (yet) 
reduced (data not shown).
One may speculate on the implications of the findings reported in this study. Increased 
concentrations of gp80 might increase the biological activity of IL-64,5 during a dialysis 
session. On the other hand, the biological effect of IL-6 is tempered by the presence of 
high concentrations of gp1303. The net result is unknown. The same can be said for the 
sTNFRs. They lower the biological effect of TNF-a, but at the same time they can serve 
as a pool for this cytokine, extending the effective presence of biological activity in 
time21. In particular with regard to the gp130 receptor, more studies need to be 
performed on its kinetics and its biological properties. This seems highly indicated, not 
only because of its importance for the biological activity of IL-6, but also because of its 
role in the signal transduction of other cytokines as interleukin-11, oncostatin-M, ciliary 
neurotrophic factor and leukemia inhibitory factor22.
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A b s t r a c t
Concentrations of interleukin-6 (IL-6), soluble IL-6 receptor (slL-6R), and soluble tumor 
necrosis factor receptor (sTNFR) p55 and p75 were measured in 25 patients with sepsis 
syndrome. Sequential blood samples were drawn from patients during a 7-h period. IL-6 
concentrations were 34-763,000 pg/ml; they were higher in non-survivors than in 
survivors but the difference was not statistically significant. In septic patients, the median 
slL-6R concentration was significantly lower than in 19 healthy volunteers (43 vs. 80 
ng/ml). slL-6R concentrations in survivors were not significantly different than those in 
non-survivors. There was a negative correlation between IL-6 and slL-6R in septic 
patients (r = -.72). In patients with moderately impaired renal function, slL-6R levels 
were not affected, but the concentrations of sTNFR's which were significantly higher.
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In tro d u ct io n
Cytokines are known to play a pivotal role in the generation of the sepsis syndrome. 
Particularly the presence of high plasma levels of cytokines such as interleukin-1 (IL-1), 
tumor necrosis factor (TNF) and IL-6 are associated with disease severity and patient 
outcome. Recently however it has become evident that not only the cytokine but also 
circulating cytokine-receptors and cytokine/cytokine-receptor complexes are involved 
in the eventual effects of cytokines in sepsis.
Soluble receptors are found for several cytokines. Examples are receptors for IL-61, and 
TNF2. These circulating cytokine receptors show a modulating effect on cytokine activity. 
For instance binding of TNF to its soluble receptor inhibits its biological effects thereby 
protecting the organism for the harmful effects of TNF excess2. Low concentrations
o
sTNFR, however, can also augment the effects of TNF by increasing its half-life . In 
contrast, soluble IL-6 receptor (slL-6R) seems to have a stimulatory effect on the 
biological activity of IL-6. It has been shown that in the presence of slL-6R, the IL-6 
stimulated production of acute phase proteins in hepatic cell cultures is enhanced4, and 
that IL-6 dependent myeloma cell lines display increased growth5.
Soluble IL-6R is a 50-55 kDa ligand binding protein that binds IL-6. It is the extra-cellular 
part of the gp80 subunit from the membrane anchored IL-6 receptor. When IL-6 is 
bound to this membrane anchored gp80, this complex associates with a signal 
transducing subunit, named gp130. Subsequently a signal is generated into the cell by 
gp1306.
In septic patients levels of circulating IL-6 correlate well with the severity of disease and 
mortality7. Since slL-6R may strongly modulate the effects of IL-6 we studied the 
circulating levels of IL-6 and slL-6R in a group of septic patients. Additionally both TNF 
soluble receptors p55 and p75 were determined in order to compare the patterns of 
these receptors and slL-6R. Different patterns were expected due to the assumed 
differences in biological function.
Ma t e r ia l s  and  m et h o d s
Patients. Sixteen men and 9 women with a mean age of 58 years (range, 18-86) 
participated in the study. They were selected from patients in the intensive care unit of 
the University Hospital Nijmegen. All study patients had sepsis syndrome according to 
the criteria of Bone8. In brief, patients had clinical evidence of infection, tachycardia, 
fever or hypothermia, and tachypnea, accompanied by at least one of the following 
manifestations of inadequate organ function or perfusion: alteration of mental status, 
hypoxemia, metabolic acidosis, oliguria, or disseminated intravascular coagulation. 
Exclusion criteria were the use of glucocorticosteroids > 20 mg per day and a creatinine 
clearance <10 ml/min. Informed consent was obtained from the patients or their 
relatives.
Nineteen of the 25 patients were in shock, defined as a sustained decrease of systolic 
bloodpressure to < 90 mmHg or a drop of systolic bloodpressure of 40 mmHg from 
baseline or any dose of vasopressors. APACHE II scores calculated over the 24 h prior 
to inclusion (mean ± SD = 20.0 ± 5.6; range 9-30). For calculation of the scores the
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Glasgow Coma Score was estimated to be normal (= 15) because most patients were 
sedated at testing.
At study entry 6 patients had a documented bacteremia, blood cultures showed Gram 
negative rods in 3 patients, Gram positive cocci in 1 patient, and a Gram negative and 
Gram positive mixed flora in 2 patients. The infectious diagnoses of the non-bacteremic 
patients included peritonitis (6), pneumonia (3), pyelonephritis (1), catheter site infection 
(2), soft tissue infection (2) and mediastinitis (1). In 4 cases no definite infectious 
diagnosis could be made. Nine patients (36%) died within 30 days after inclusion. The 
estimated mortality rate for our patient group according to the calculated APACHE II 
score is 30-40%.
Patients samples. After inclusion 6 blood samples were taken, starting 30 min before 
the first antibiotic gift and than 0, 1, 2, 4, 6 h after this start. Serum samples were 
allowed to clot at room temperature and after centrifugation serum was collected. 
Plasma was collected in 4 ml tubes (Vacutainer System; Becton Dickinson, Rutherford, 
NJ) containing 48 //I of 15% EDTA(K3) and 250 fj\ aprotinin (Bayer, Leverkusen, 
Germany). Serum and plasma was stored at -20°C until determination.
Control samples. As a control one blood sample was taken from 19 healthy hospital 
employees. Data on age and sex were not collected.
IL-6 and slL-6R ELISA. IL-6 and slL-6R ELISA’s were used as described before6. 
Detection ranges of the ELISA’s were 20-800 pg/ml (IL-6), and 0.4-25 ng/ml (slL-6R). 
Nor the addition of IL-6 to slL-6R nor the addition of slL-6R to IL-6 influenced the 
detection of the cytokine or its soluble receptor6. IL-6 and slL-6R were determined in 
serum.
sTNFR p55 andp75 determination. Both receptors were determined in plasma using an 
Enzyme Linked Immuno-Binding Assay (kindly provided by H. Gallati, Hoffmann-La 
Roche, Basel Switzerland). Detection levels for p55 and p75 were 80 pg/ml and 300 
pg/ml respectively. Normal values in healthy volunteers are 1470 ± 190 pg/ml for p55 
and 2520 ± 660 pg/ml (mean ± SD) for p759.
Statistical analysis. Spearman correlation coefficients are used to calculate the relation 
between IL-6 and slL-6R levels and APACHE II scores. Differences between groups are 
tested using the Wilcoxon rank sum test. Differences are considered significant with a 
two tailed P-value < .05.
R e s u l t s
Over the 7 hour study period, which began 30 min before the first antibiotic gift, the 
mean coefficient of variation for slL-6R and IL-6 in the individual septic patients was 
16% and 36% respectively, thus showing only minor variations. Figure 1 shows the 
median values for each individual patient.
IL-6 concentrations were elevated in all patients showing a large range from 34-736.000 
pg/ml. Although not statistically significant (P = .4), median IL-6 concentrations in the 
non-survivor group (3060 pg/ml) were higher than in the survivor group (988 pg/ml). IL-6 
concentrations in the healthy volunteers were all below the detection limit (< 20 pg/ml) 
and statistically different from the patients (P < .0001).
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Median level of circulating slL-6R in these healthy volunteers was 80 ng/ml (range: 46 
-115 ng/ml). In septic patients, however, slL-6R levels were significantly reduced 
(median 43 ng/ml, range 10-165 ng/ml) compared to the normal controls (P = .0001). 
There was a strong negative correlation between median levels of IL-6 and the 
accompanying slL-6R in septic patients, Spearman correlation coefficient for the median 
levels of IL-6 and their accompanying slL-6R levels was -.72 (P = .0001 ).
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Figure 1: Median IL-6 and slL-6R concentrations of each individual patient subdivided into 
non-survivors (NS) and sun/ivors (S), and the concentrations found in the single sample of the 
healthy control group (C). *: P > .05, -J-: P = .0001, =f: P < 0.0001 (Wilcoxon Rank Sum test).
The median levels of IL-6 for each patient correlated well with the APACHE II score. 
Spearman correlation coefficient (r) was .50 (P = .01). For the median slL-6R levels no 
significant correlation was found with the APACHE II score. When the IL-6/slL-6R ratio 
is calculated and related to APACHE II scores the Spearman correlation coefficient 
remained the same as for IL-6 alone (r = .50, P = .01).
Soluble TNFR p55 and p75 concentrations were also determined in the septic patients. 
The mean coefficient of variation for sTNFR p55 and p75 were 8% and 10% 
respectively, indicating a stable concentration during the study period. sTNFR 
concentrations, determined in 23 patients, ranged from 2.4 - 30.9 ng/ml for p55 and 
from 5.4 - 75.8 ng/ml for p75. Both receptor levels did not significantly differ between
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survivors and non-survivors during the 7 hour study period. There was no significant 
correlation between sTNFR's and slL-6R.
To investigate the role of renal function in maintaining soluble receptor levels, patients 
were divided into a group with normal renal function (creatinine concentration range 0.6 
-1.9 mg/100 ml, n = 18) and a group with renal impairment (creatinine concentration 
range 2.0 - 3.4 mg/100ml, n = 7). Median concentrations of sll_-6R in patients with 
normal renal function (43.3 ng/ml) did not significantly differ from patients with renal 
impairment (43.0 ng/ml). However, sTNFR p55 and p75 levels were significantly higher 
in patients with renal impairment (p55: 17.6 ng/ml; p75: 31.6 ng/ml) compared to 
patients with normal renal function (p55: 6.4 ng/ml, P < .001; p75:11.7 ng/ml, P < .005).
D is c u s s io n
The principal finding in this study was that patients with sepsis syndrome have 
decreased concentrations of slL-6R with concomitantly high concentrations of IL-6 in the 
circulation.
The concentrations of slL-6R we found in normal volunteers are comparable to those 
described in literature1,5. Compared to this control group, septic patients have 
significantly lower concentrations of slL-6R. These data are in contrast to the findings 
reported in HIV-seropositives and patients with monoclonal gammopathy showing 
elevated levels of slL-6R compared to control groups1,5. These diseases are obviously
fundamentally different from sepsis, but increased IL-6 concentrations have been
10 11described in sepsis as well as in HIV-seropositives and monoclonal gammopathy ’ 
Apparently in HIV-seropositives and patients with monoclonal gammopathy the relation 
between IL-6 and slL-6R is different from the one in sepsis; a study in these patients 
measuring both IL-6 and slL-6R, however, has not yet been published to our knowledge. 
How slL-6R concentrations are regulated is not clear. Possibly the IL-6/slL-6R complex 
is internalized by the effector cells resulting in a decreased expression of gp80 on the 
cell surface12. With the assumption that membrane anchored IL-6R is the main source 
of slL-6R, the increased turnover of membrane anchored IL-6R in the presence of high 
levels of IL-6 might be responsible for the decreased levels of slL-6R.
It is known that slL-6R is generated either by shedding of the membrane anchored 
gp8013 or by direct production of a slL-6R form through transcription of a specific 
mRNA14. How this production is regulated still has to be determined. In case of 
shedding, protein kinase C (PKC) seems to play an important role. Inhibitors of PKC 
might have a down regulating effect on the slL-6R production. IL-6 itself seems to have 
no effect on shedding of the gp80 ligand binding protein13. Snyers and Content show 
that the expression of the gp130 component of the IL-6R is enhanced by IL-615. The 
expression of both components however, may be regulated by different mechanisms. 
Preliminary results of ex-vivo whole blood assays suggest that circulating cells are 
probably not involved in the production or use of slL-6R. When LPS is added to whole 
blood IL-6 is produced in large amounts (up to 100,000 pg/ml). The concentration of sIL- 
6R however does not change compared to the control bloodsample without addition of 
LPS (unpublished results).
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Other researchers have also found elevated TNF receptors in patients with severe 
infections (e.g. sepsis, malaria and meningococcemia). In our study group both TNF and 
IL-6 were increased during sepsis, but the pattern of their soluble receptors is different 
and the concentrations were not correlated. These findings suggest a different biological 
role for both cytokine receptors: sTNF-R may inhibit whereas slL-6R enhances the 
biological effects of TNFct and IL-6 respectively.
It is well known that concentrations of sTNFR's in sepsis are influenced by renal 
function16. In this study we confirm that septic patients with renal impairment have 
higher sTNFR concentrations. For slL-6R, no relation with the creatinine levels is found. 
This suggests that the renal clearance of slL-6R is not an important way to regulate sIL- 
6R levels, which is supported by the notion that only small amounts of slL-6R are found 
in urine of healthy humans in comparison to circulating concentrations6. However, 
because patients with a renal clearance <10 ml/min were excluded in this study no 
definitive conclusions can be drawn. Preliminary results in patients with chronic 
hemodialysis indicate an increase in basal levels of slL-6R. This means that moderate 
renal impairment does influence sTNFR concentrations but not slL-6R concentrations. 
In previous in vitro studies the biological effects of slL-6R4,5 were found to be different 
from the biological effects of the sTNFR2. Here we demonstrate that the in vivo pattern 
of slL-6R in septic patients is also different from the sTNFR. We can only speculate on 
the biological significance of the reduction of slL-6R during sepsis. It might be a way to 
decrease the biological activity of IL-6 or just a result of internalisation of IL-6 together 
with its receptor.
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A bstract
Objective:
To determine the pattern of the soluble interleukin-6 receptor during acute 
meningococcal infections and recovery phase. In addition the effect of plasma or 
whole blood exchange on the plasmaconcentrations of these mediators was 
measured.
Design:
Prospective, descriptive patient study.
Setting:
University Hospital Intensive care unit.
Patients:
Patients with bacteriologically proven meningococcal infections were entered in the 
study. Three group were formed: group A with meningitis, group B with meningitis 
and shock, and group C with shock only.
Interventions:
Part of the patients with shock underwent plasma or whole blood exchange. 
Measurements:
Serum concentrations of IL-6 and soluble IL-6 receptor were determined sequentially 
during the acute and recovery phase.
Main results:
Peak concentrations of IL-6 were highest in group C followed by group B and A. 
Soluble IL-6 receptor concentrations showed an opposite pattern and were all below 
normal. Soluble IL-6 receptor concentrations were negatively correlated with the IL-6 
concentrations. During recovery IL-6 rapidly decreased and soluble IL-6 receptor 
increased to supranormal concentrations whereafter they returned to normal. Plasma 
or whole blood exchange did not significantly influence IL-6 concentrations but did 
increase the soluble IL-6 receptor concentration directly after an exchange session 
followed by a rapid decline.
Conclusions:
Soluble IL-6 receptor concentrations are low in acute meningococcal infections. 
Plasma or whole blood exchange temporarily increases these concentrations. It 
needs to be determined whether the effect of this therapy is beneficial to the patient.
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In tro d u c t io n
Among the acute bacterial infections, meningococcal infections are one of the most 
lifethreatening diseases. The Gram negative bacterium Neisseria meningitides can 
induce a clinical disease that varies from meningitis to a rapidly deteriorating sepsis 
syndrome with severe shock and a mortality of 30-70%1. High concentrations of the 
pro-inflammatory cytokines interleukin-6 (IL-6) and tumor necrosis factor (TNF), are 
found in these patients, and these cytokine concentrations correlate with disease 
severity and outcome2,3,4. The role of IL-6 in the pathogenesis of septic shock has 
not been elucidated. An important function for IL-6 is presumably to act as a 
mediator between damaged tissues and the liver, where it is a potent inducer of 
acute phase proteins.
Soluble receptors for various cytokines have been shown to modulate the biological 
effects of their ligand5. TNF activity, for example is decreased in the presence of 
soluble TNF receptor by competitive inhibition6; in contrast low concentrations of 
soluble TNF receptor can increase the effects of TNF by prolonging its half-life7. 
Soluble IL-6 receptor, however, seems to play a different modulating effect on IL-6 
activity. The ligand binding part of the cellular IL-6 receptor (gp80) is either shed from 
the surface or secreted by the cell8,9. A complex of the soluble IL-6 receptor and IL-6 
can interact with the signal transducing part of the cellular IL-6 receptor (gp130) and
generate a signal into the cell. Through this mechanism the presence of soluble IL-6
10 11receptor enhances the biological activity of IL-6 ’ . Studies on the patterns and 
effects of this soluble receptor are necessary to understand the biological 
significance of this phenomenon.
We studied the pattern of IL-6 and its soluble receptor in the acute and recovery 
phase of meningococcal infections. A number of the study patients underwent 
plasma or whole blood exchange which possibly improves clinical signs of sepsis 
and survival12,13,14,15. Because the mechanism behind the beneficial effect of this 
procedure has not been elucidated yet, the effect of plasma or whole blood 
exchange on the patterns of the plasmaconcentrations of IL-6 and soluble IL-6 
receptor was also measured in this study.
Ma t e r ia l s  an d  m e t h o d s .
Patients with bacteriologically proven meningococcal infections admitted to the 
intensive care unit were included in the study. Cultures for Neisseria meningitides 
had to be positive from at least one of the following sites: blood, cerebrospinal fluid 
(CSF), and/or skin lesion. According to Halstensen16 three groups were 
discriminated. Group A (n=13) showed a meningococcal infection of the central 
nervous system without shock; group B (n=5) an infection of the central nervous 
system plus shock; and group C (n=5) showed no infection of the central nervous 
system but only shock. Infection of the central nervous system was defined as a 
leukocyte count >100*106/l in CSF. Shock was defined prospectively as a systolic 
blood pressure during the first hours after admission <100 mmHg in patients over 14 
years, <85 mmHg in children younger than 14 years, and <75 mmHg in patients
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under 4 years. Demographics of the patients are given in table 1. Four patients in 
group B, and all patients in group C underwent plasma or whole blood exchange11. In 
patients with <25 kg body-weight, 50-60 ml whole blood per kilogram was exchanged 
each session. In patients > 25 kg body weight, 30-40 ml plasma per kilogram was 
exchanged with fresh frozen plasma each session. The exchange was started as 
soon as possible after admission and was repeated after 12 hours. When the 
patients' condition remained critical the exchange was repeated 24 and 48 hours 
later.
After admission serum samples were collected serially during the first day and each 
following day. Blood was allowed to clot before centrifugation and serum was stored 
at -20°C until tested. Samples were also taken directly before and after the exchange 
of plasma or blood.
Table 1 : Patient demographics.
Group A Group B Group C
Number of patients 13 5 5
Male/Female 5/8 3/2 4/1
Age* (y) 15(2-64) 15(0-17) 8(2-18)
Prehospital disease
period* (h) 23.5(12.5-84) 14 (5-30) 14 (7-16.5)#
Mortality (n) 1 1 2
PE/BE** (n/n) 0/0 3/1 3/2
Leukocytes in CSF
(106/l) 21674 (3900-70000) 417(107-6000/ 14(1-45)*®
#= significantly different from group A 
@= significantly different from group B 
* = medians; range between parenthesis 
** PE= plasma exchange, BE= blood exchange
Soluble IL-6 receptor and IL-6 were determined by Enzyme Linked Immunosorbent 
Assays (ELISA's) as described before17. These ELISA's are not influenced by the 
presence of soluble IL-6 receptor in the IL-6 ELISA or IL-6 in the soluble IL-6 
receptor ELISA17. Detection limit of the IL-6 ELISA is 20 pg/ml, of the soluble IL-6 
receptor ELISA 0.4 ng/ml. Concentrations in normal volunteers for IL-6 and soluble 
IL-6 receptor are <20 pg/ml and 76.6 ± 19.3 ng/ml (mean ± SD) respectively17. 
Statistical analysis: Differences between groups were calculated with the Wilcoxon 
rank sum test. Differences were considered significant with a two tailed p-value <.05. 
Relations between IL-6 and soluble IL-6 receptor were calculated using the 
Spearman correlation coefficient.
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Results
Figure 1 shows the peak concentrations of IL-6 and concomitant soluble IL-6 
receptor concentration for each individual patient subdivided into the three groups. 
Median IL-6 peak concentrations in group A were 703 pg/mi, in group B: 6942 pg/ml, 
and in group C: 120800 pg/ml. For soluble IL-6 receptor this was 56 ng/ml in group 
A, 12 ng/ml in group B, and 7 ng/ml in group C. The peak values for IL-6 differed 
significantly between group A and B (p=.0009), and A and C (p=.0002), but not 
between B and C (p=.31). For soluble IL-6 receptor concentrations the differences 
between group A and B and A and C were significant (p=.0009 and .0005 
respectively), there was no statistically significant difference between group B and C 
(p=42).
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Figure 1: Peak IL-6 and corresponding slL-6R concentrations
Peak concentrations for IL-6 and soluble IL-6 receptor of each individual patient, medians 
are indicated (A vs B, and A vs C: p<.001). A, B, and C represent the groups as described in 
the materials and methods section.
All patients in each group had detectable IL-6 concentrations on entry in the study 
which gradually decreased during recovery. In contrast, soluble IL-6 receptor 
concentrations were low at admission and increased to normal concentrations after a 
rebound. IL-6 concentrations returned to normal after approximately 48 hours.
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Figure 2: IL-6 patterns 
Patterns of IL-6 of all patients in group A, 
B, and C (see patients and methods). 
Solid lines indicate plasma or whole blood 
exchange sessions (note the different 
axes lengths).
Figure 3 : slL-6R patterns 
Patterns of soluble IL-6 receptor of all 
patients in group A, B, and C (see patients 
and methods). Solid lines indicate plasma 
or whole blood exchange sessions (note 
the different axes lengths).
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Soluble IL-6 receptor concentrations, however, returned to normal ranges only after 
120-160 hours.
There was a strong negative correlation between IL-6 and Soluble IL-6 receptor. For 
the peak concentration of IL-6 the Spearman correlation coefficient was -0.82.
Figure 2 shows the patterns of IL-6 and figure 3 the patterns of soluble IL-6 receptor 
over time in all patients of each group. In patients who underwent plasma or whole 
blood exchange the sessions are indicated by thick lines. Soluble IL-6 receptor 
concentration is temporarily increased after a plasma or whole blood exchange 
session. At the onset of the disease, when IL-6 concentrations are high this increase 
of soluble IL-6 receptor concentration is quickly nullified. At low IL-6 concentrations 
the effect of plasma exchange is followed by a rise in soluble IL-6 receptor 
concentration. This can be visualised by the calculation of the change of soluble IL-6 
receptor concentration per hour after an exchange session by the following formula:
[soluble IL-6 receptoi]B-[soluble IL-6 receptoi]A 
hours between A and B
where [soluble IL-6 receptof\A is the concentration of soluble IL-6 receptor in ng/ml 
measured just after an exchange session and [soluble IL-6 receptoi]B is the 
concentration of soluble IL-6 receptor in ng/ml measured in the next sample after A. 
Negative changes therefore mean that the soluble IL-6 receptor concentration 
decreases after an exchange session and positive changes mean that the soluble IL- 
6 receptor concentration increases after the exchange session. Figure 4 shows the 
calculated changes in relation to the IL-6 concentration at point A. Spearman 
correlation coefficient is -0.81 (p<.0001).
IL-6 (pg/ml)
Figure 4: slL-6R kinetics
The change of soluble IL-6 receptor concentration per hour (for the formula see results 
section) after a plasma or whole blood exchange session related to the IL-6 concentration. 
Dashed lines indicate the 95% confidence interval.
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D isc ussio n .
Our data confirm previous studies showing that severity of meningococcal disease is 
correlated with the serum IL-6 concentration3. Groups A, B and C respectively show 
increasing peak concentrations of IL-6. For soluble IL-6 receptor the opposite pattern 
is found: increasing severity of disease is correlated with decreasing concentrations 
of soluble IL-6 receptor. A strong negative correlation is found for IL-6 and soluble IL- 
6 receptor, indicating a close relation of these two parameters.
Recently we reported that the soluble IL-6R concentration was decreased in sepsis 
compared to healthy humans18. Here we confirm this finding for patients with 
meningococcal infection. Patients from group A without septic symptoms also 
showed low concentrations of soluble IL-6 receptor indicating that sepsis is not 
obligatory for soluble IL-6 receptor to be decreased. The concentration of IL-6 
appears to be the main determinant for the soluble IL-6 receptor concentration which 
is in agreement with the negative correlation between IL-6 and soluble IL-6 receptor 
as shown in figure 2 and 3.
The rebound phenomenon we see in the patients who have undetectable 
concentrations of IL-6 could be explained by a delay in the regulation of soluble IL-6 
receptor concentrations. Assuming that under conditions with high IL-6 
concentrations soluble IL-6 receptor or IL-6/soluble IL-6 receptor complexes are 
rapidly cleared from the circulation, a counter regulation starts leading to increased 
production or shedding of soluble IL-6 receptor. If this increased production 
continues when the clearance of soluble IL-6 receptor decreases it will result in a 
temporarily higher soluble IL-6 receptor concentration.
The concentrations of soluble IL-6 receptor in the patients undergoing plasma or 
whole blood exchange are markedly increased after an exchange session. This can 
be explained by the fact that plasma with a relatively low concentration of soluble IL- 
6 receptor is partially replaced with plasma containing normal concentrations of 
soluble IL-6 receptor. Plasma soluble IL-6 receptor concentration of one patient for 
instance was 5 ng/ml before and 30 ng/ml after the first whole blood exchange 
session. 2400 ml blood was exchanged in 8 portions. If the mixture of donorblood 
with the patientsblood after each portion is taken into account and the 
plasmaconcentration of the donorblood is estimated to be 80 ng/ml soluble IL-6 
receptor, the concentration in the patients plasma would be ± 39 ng/ml at the end of 
the session. The difference with the actual concentration could be the effect of 
ongoing clearance of soluble IL-6 receptor either or not complexed with IL-6. The 
exchange session did not significantly influence the IL-6 concentration. Whether the 
increase in soluble IL-6 receptor is of benefit for the patient needs to be determined, 
because increasing the biological activity of IL-6 by soluble IL-6 receptor might harm 
the patient. Still beneficial effects of plasma or whole blood exchange are reported. 
Probably the cytokines are not the one and only determinant for the outcome of 
sepsis patients, as is also indicated by lack of efficacy of cytokine antagonists in
19clinical trials .
After an exchange session the soluble IL-6 receptor concentration rapidly declines 
which indicates that the turnover of soluble IL-6 receptor is high. The rate of decline
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is dependent on the IL-6 concentration. In an early phase of the illness when high IL- 
6 concentrations circulate the amount of soluble IL-6 receptor present in the 
exchanged plasma is much quicker cleared than in a later phase when plasma IL-6 
concentrations are low. When IL-6 concentrations have decreased, the soluble IL-6 
receptor concentration does not decrease any more after an exchange session but 
even increases. This indicates that IL-6 is an important factor for the clearance of 
soluble IL-6 receptor. In vitro studies however are not conclusive on the effect of IL-6 
on the IL-6R expression or soluble IL-6 receptor production. Some reports indicate a 
decrease of the expression of IL-6R20’21 but another shows no effect22. These studies 
are performed on different cell types under different conditions, which cells are 
involved in vivo is not clear. On the mode of clearance of soluble IL-6 receptor very 
little is known. Soluble IL-6 receptor is found in the urine in only little amounts, and 
moderate renal impairment does not seem to influence the soluble IL-6 receptor 
concentration18, but preliminary results of studies in patients with almost absent renal 
function do indicate a role for the kidney in maintaining soluble IL-6 receptor 
concentrations (manuscript in preparation).
To our knowledge this study is the first which strongly indicates an important role for 
IL-6 in maintaining soluble IL-6 receptor concentrations and in clearance of the 
soluble IL-6 receptor and is performed in patients. Studies on the underlying 
mechanisms, however, still have to be done.
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A b s t r a c t
In 39 patients with acute meningococcal infections, the plasma concentrations of 
tumor necrosis factor-ff (TNF) and its soluble receptors TNFsR-p55 and TNFsR-p75 
were measured from admission till recovery.
At admission, patients with shock had significantly higher TNF, TNFsR-p55 and 
TNFsR-p75 values than patients without shock. In addition, during the first 24 h, 
shock patients had higher TNFsR-p75 to TNFsR-p55 ratios, indicating that in shock 
the increase of TNFsR-p75 exceeds that of TNFsR-p55. TNF measured more than 
12 h after admission failed to differentiate between shock and non-shock because 
TNF normalized within 12 - 24 h. However, because TNFsRs remained elevated for
5 to 6 days, at that time plasma TNFsRs still differentiated between shock and non­
shock.
Plasma exchange or whole blood exchange (PEBE), performed in 20 shock patients, 
accelerated the decrease of plasma TNFsRs. However, due to a rebound after each 
PEBE session, the overall half-lives of both TNFsRs were not affected by PEBE.
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In tro d u c t io n
Tumor necrosis factor-a (TNF) is a pivotal mediator in the pathogenesis of 
meningococcal infections1,2. The biological activity of TNF is mediated via two TNF 
receptors on the target cell, named TNFR-I or TNFR-p55 and TNF-RII or TNFR- 
p753,4. Cells can modulate their sensitivity to TNF, by shedding the extracellular part 
of these receptors5. The resultant increased concentrations of TNF soluble receptors 
(TNFsRs), further impedes TNF bio-activity by preventing the binding of TNF to cell- 
associated receptors6,7. However, the presence of TNFsR may also prolong the 
activity of TNF, as the complexed TNF can dissociate later in the course of the 
disease8. Because of these TNF-modulating effects, and because of the interference 
of TNFsRs on some TNF laboratory assays9,10, insight in the kinetic behaviour of 
TNFsRs may be of help for a correct understanding of the biological role of TNF. 
Experimental studies using bolus infusions of live bacteria11, endotoxin12,13, various 
cytokines14'17 or anti-CD3 antibodies18 suggest different kinetics for TNF and TNFsR. 
Similarly, clinical observational studies showed persistently elevated TNFsR levels in 
patients with sepsis of various etiologies19'22. From these studies it appeared that the 
severity of the infectious insult determines the initial release of TNF and TNFsR. 
However, the kinetic behaviour of TNFsR appeared to be determined principally by 
the renal function23'25.
To date, only limited data is available on the kinetic behaviour of sTNFR in relation to 
that of TNF in patients with a well defined uniform infection and normal renal 
function. Therefore, we studied the kinetics of TNF, TNFsR-p55 and TNFsR-p75 
from admission till recovery in acute meningococcal infections, the prototype human 
disease of overwhelming endotoxin exposure. Because some of these patients were 
treated with plasma exchange or whole blood exchange (PEBE)26, the influence of 
this treatment on the kinetics of TNFsRs was also studied.
P a t ie n t s  and  m et h o d s
Patients. The study group comprised 39 patients with life-threatening meningococcal 
infections admitted from November 1990 to August 1995 at the Intensive Care Unit 
(ICU) of the University Hospital Nijmegen (n = 34) and the Eemland Hospital, 
Amersfoort (n = 5). Patients were prospectively classified according to the absence 
(/? = 15) or presence (n = 24) of shock. Shock was defined by the occurrence of 
hypotension refractory to fluid resuscitation and requiring inotropic or vasoactive 
support; hypotension was defined as a systolic blood pressure <100 mm Hg in 
adults, < 85 mm Hg in children younger than 14 years, and < 75 mm Hg in children 
younger than 4 years2. The non-shock patients had a Niklasson prognostic score of 
median 1 (range, 1 - 2), the shock group had a median score of 4 (range, 2 - 6)27. 
Table 1 shows other prognostically relevant characteristics. All patients were treated 
with antibiotics starting immediately after admission; 37 patients received steroids in 
a dosage equivalent to 0.6 mg/kg/day dexamethasone (DXM) for 3 days. None of the 
patients participated in a treatment trial for sepsis.
Twenty of the 24 shock patients (17 survivors and 3 non-survivors) were treated with
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additional PEBE as reported previously26. In brief, in each plasma exchange (PE) 
session, performed in patients > 25 kg, 30 - 40 mL/kg plasma was exchanged for 
fresh frozen plasma. In each blood exchange (BE) session, performed in children < 
25 kg, 50 - 60 ml/kg whole blood was exchanged for citrate anticoagulated whole 
blood. PEBE was started as soon as possible after entry to the ICU and repeated 
after 12, 24 and 48 h if the condition of the patient was still critical. One PEBE 
session took 1 - 2 h. The effect of PEBE on the endotoxin pattern in 6 patients of the 
present study was reported previously26; the admission data of some pro- and anti­
inflammatory cytokines of 30 patients have been published elsewhere2; the pattern of 
interleukin-1 ft (IL-1R) and its modulating agents in 34 of the patients was reported
29recently .
Tab le 1: Demographic and disease characteristics of 39 patients with acute 
meningococcal infections. Data are number or median (range).
Non-shock (n = 15) Shock(n = 24) P-value
Female /Male 7/8 15/9
Age, years 15 5 .008
(2-64) (0 - 30)
Duration of disease 22 12 .0001
before hospital (12-84) (2.8 - 30)
admission, h
Leukocytes in cere­ 13,800 95 <.0001
brospinal fluid, x 106/L (>100-70,000) (1 - 19,800)
Peripheral leukocy­ 19.3 4.3 <.0001
tes3, x106/L (11.0-28.7) (1.4-26.8)
Platelets9, x 109/L 155 62 .0007
(51 - 220) (16-325)
Fibrinogen3, mg/L 4,840 1,680 <.0001
(3,500- 12,000) (90-4,160)
Lactate3, //mol/L 2,600 5,120 .0005
(700 - 4,070) (1,530-12,700)
Creatinineb, % 128 217 .0005
(91 - 333) (110-400)
Fatalities 0 5 n.s.
NOTE: a Nadir within 12 h after hospital admission.
b Percentage of age and gender adjusted normal value (see ref 28).
76
Chapter 6
All 15 non-shock patients survived, two suffered from sensorineural deafness. Five 
shock patients died: two died after 2.5 and 10 h without PEBE and two died 18 and 
28 hours post-admission when 2 PEBE sessions had been performed. One patient 
died after 4 PEBE sessions when treatment was stopped 4 days after admission 
because of severely mutilating gangrene, acidosis and anuria.
Blood sampling. Blood sampling for assays of plasma TNF, TNFsR-p55 and TNFsR- 
p75, started median 3.0 h (range 0.0 -11.1) after hospital admission and stopped - in 
survivors - after median 156 h (46 - 210). Samples were drawn at frequent intervals 
during the first 2 days and once daily from day 3 to 7. To quantitate the effect of 
PEBE on the kinetics of TNFsR-p55 and TNFsR-p75, 15 of the 20 patients treated 
with PEBE (12 survivors and 3 non-survivors) had blood sampled exactly before and 
after each PEBE session. After sampling, blood was centrifuged immediately twice 
and plasma or serum was stored at -20°C until assay.
Measurement of TNF, TNFsR-p55, TNFsR-p75 and creatinine. TNF, TNFsR-p55 and 
TNFsR-p75 were determined in platelet-poor EDTA-plasma. TNF was determined by 
a radio-immuno assay (RIA)2,30. The normal value of TNF, as measured in 143 
healthy controls, was 94 ± 22 pg/mL (mean ± SD). The assay detects both free and 
bound TNF. TNFsR-p55 and TNFsR-p75 were measured by enzyme linked 
immunobinding assays (Hoffmann-La Roche, Basel, Switzerland). These assays 
were not influenced by the addition of human recombinant TNF. Normal values for 
TNFsR-p55 were 1470 ±190 pg/mL and for TNFsR-p75 2520 ± 660 pg/mL. The ratio 
TNFsR-p75 to TNFsR-p55 in healthy controls was median 1.7 (range, 1.2 - 2.2). 
Serum creatinine was measured by routine hospital laboratory procedures with a 
Hitachi 747 automatic analyzer. The creatinine values are expressed as a 
percentage of normal values adjusted to age and gender28.
Calculations and statistics. The elimination of TNFsR-p55 and TNFsR-p75 was 
estimated with a log-linear model, described by the formula:
In (C j( t )  -  Cnormal) =  3o  3 / +  k . t  (7 = 1 ,...1-1)
= ao + k.t (i - 1)
with: C i( t)  : plasma concentration of the i-th patient at time t
Cnorma\ '■ the upper normal reference range expressed as mean + 2SD,
1850 pg/mL for TNFsR-p55 and 3840 pg/mL for TNFsR-p75
I : number of patients 
ao, a, : intercept parameters 
k : slope parameter 
The parameters ao, a-,, and k were calculated with multiple linear regression. The 
mean half-lives (i.e. In 2/-k) were compared with by a Student t-test. A Mann-Whitney 
U-test or Fisher's Exact test was used to compare non-shock and shock patients. P- 
values of .05 or less were considered significant.
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Figure 1: Plasma concentrations of tumor necrosis factor-o (TNFa) and its soluble 
receptors TNFsR-p55 and TNFsR-p75 in 15 patients with acute meningococcal infections 
without shock (white bars) and 19 surviving patients with shock (hatched bars), daily from 
admission up to day 6. The grey area indicates the normal range (mean ± 2 x SD). Box- 
whisker plots: horizontal line = median, box = 25th to 75th percentiles, whiskers = 5th to 95th 
percentiles. A Mann-Whitney U-test was used to compare non-shock and shock patients: * 
P <.05; **, P <.01; ***, P <.001.
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Table 2. Half-lives (t1A) for tumor necrosis factor soluble receptor-p55 (TNFsR-p55) 
and TNFsR-p75, before, during and after subsequent plasma exchange or whole blood 
exchange (PEBE) procedures.
Period
No. of 
observations
t1A for TNFsR-p55 
(h)
VÆ for TNFsR-p75 
(h)
Directly after 
admission 12 6.9 ±5.1 7.7 ±4.6
During 1st 
PEBE-session 12 2.5 ± 1.3 2.4 ± 1.1
Between 1st and 
2nd PEBE-session 12 >350 >50
During 2nd 
PEBE-session 12 3.9 ±5.0 2.4 ±2.1
Between 2nd and 
3rd PEBE-session 10 no real figure* no real figure*
During 3rd 
PEBE-session 10 2.3 ± 1.3 2.4 ± 1.7
Note: # due to an increase of TNFsR over this period, the mean half-lives turned out 
to be "negative".
Results
At admission, the plasma TNF concentration in patients without shock was median
101 pg/mL (range, 60 to 182). In patients with shock TNF was 323 pg/mL (range, 55 
to 1800) (P = .0003) for the complete group, and 262 pg/mL (range, 55 to 855) for 
surviving shock patients (P = .002). Plasma TNF normalized within one day. TNF of 
non-shock and shock patients, measured in later stages did not differ significantly 
(Fig 1, upper panel). This contrasted to the plasma concentrations of TNFsR-p55 
and TNFsR-p75, who were persistently and significantly more elevated in shock than 
in non-shock throughout the whole observation period (Fig 1, lower panels).
Median TNFsR-p55 and TNFsR-p75 at admission in non-shock patients were 
respectively 4,520 pg/mL (range, 2,330 to 8,940) and 9,410 pg/mL (range, 5,060 to 
32,080). In surviving shock patients these values were 13,900 pg/mL (range, 2,630 
to 29,300) and 32,930 pg/mL (range, 12,220 - 98,710) (both P <.0001). The ratio 
TNFsR-p75 to TNFsR-p55 at admission for non-shock patients was median 2.2 
(range, 1.4 to 4.0). This was sligthly but significantly higher than for healthy controls 
(P = .009). For shock patients however, this ratio was much higher, median 3.4 
(range, 1.8 to 6.2) (P = <.0001). As can be seen in Figure 2, the ratio normalized 
gradually during recovery.
79
TNF and TNF soluble receptors in meningococcal infections
7 
6 
5 
4 
3 
2 
1 
0
0 2 4  48 72  96  120  1 4 4  168  192
7
6
5 
4
3
2
1 
0
0 2 4  48  72 96  120  1 4 4  168  192  
time after adm ission (h)
Figure 2: The ratio of the plasma concentration of tumor necrosis factor soluble 
receptor-p75 (TNFsR-p75) to TNFsR-p55, during the first 7 days after admission in patients 
with acute meningococcal infections. Panel A shows 144 ratios of 15 surviving patients 
without shock (open dots). Panel B shows 266 ratios of 24 patients with shock; closed dots 
indicate data from surviving patients, crosses are from fatalities. The dashed and solid lines 
are the best logarithmical fitting. The grey area indicates the normal range (mean ± 2  x SD).
Serum creatinine at admission in surviving shock patients was higher than in non­
shock (P = .002), but normalized rapidly. At day 2 the median creatinine value in 
shock patients was 99% (range, 45 to 141), which did not differ significantly from that 
in non-shock patients.
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Figure 3: The course of the plasma concentrations of tumor necrosis factor soluble 
receptor-p55 (TNFsR-p55) (open circles or triangles) and TNFsR-p75 (dosed circles or 
triangles) in two representative patients indicated with respectively circles or triangles. Both 
patients were treated with additional plasma exchange (PE); PE sessions are indicated by 
thick lines.
The course of plasma TNFsR showed a biphasic pattern with a rapid decline initially 
and a slower decrease during further recovery. In spite of the rapid normalization of 
renal function, still 50% of the non-shock and 82 % of the surviving shock patients 
had increased TNFsR values at day 4. The mean half-lives for TNFsR-p55 and 
TNFsR-p75 over the complete observation period in patients not treated with PEBE 
were 61 ± 40 h and 53 ± 32 h, respectively. In patients treated with PEBE, the overall 
half-life was not significantly different, 81 ± 26 h and 70 ± 22 h, respectively. 
However, detailed measurements just before and after PEBE sessions showed that 
PEBE influenced the TNFsR plasma pattern importantly, although this effect was 
only short-lasting (Fig 3 and Table 2).
81
TNF and TNF soluble receptors in meningococcal infections
D iscussion
In this study it is shown that, in patients with acute meningococcal infections, the 
plasma concentrations of TNF and its soluble receptors TNFsR-p55 and TNFsR-p75 
follow different kinetics. At admission, patients with shock had significantly higher 
plasma TNF, TNFsR-p75 and TNFsR-p55 concentrations as compared to non-shock 
patients. In addition, patients with shock had higher TNFsR-p75 to TNFsR-p55 ratios 
indicating that TNFsR-p75 was more elevated than TNFsR-p55. As plasma TNF 
normalized within one day, TNF measured more than 12 h after admission failed to 
differentiate between non-shock and shock. In contrast, plasma TNFsRs normalized 
only slowly over 5 to 6 days, in spite of a rapid restoration of the renal function within 
2 days. Therefore, TNFsRs measured in the subacute stage still differentiated 
between non-shock and shock. PEBE influenced the plasma pattern of both TNFsRs 
by accelerating the decrease of plasma TNFsRs. However, as a rebound of TNFsR 
occurred after each PEBE session, PEBE did not significantly affect the overall half- 
life of TNFsR-p55 and TNFsR-p75.
The increased ratio of TNFsR-p75 to TNFsR-p55 in shock patients with extensive 
skin necrosis in the present study might reflect that the p55-receptor is less easily 
shedded than the p75-receptor. This may be important for the toxic endotoxin effects 
such as shock, coagulation activation and skin necrosis31'36, that are mainly 
mediated via the p55-receptor. Another explanation for the increased TNFsR-p75 to 
TNFsR-p55 ratio, might be found in the excessive activation of complement, 
granulocytes and endothelium during the initial stage of meningococcal shock37,38. 
Activated complement is believed to contribute to the shedding of TNFsR, as in 
experimental sepsis, shed TNFsRs appear in the circulation before the appearance
39of cytokines . In addition, TNF stimulated granulocytes shed selectively the p75 
receptor40, and endothelial cells express more TNFR-p75 than TNFR-p5541,42. Thus, 
the higher TNFsR-p75 to TNFsR-p55 ratio might be a reflection of these 
pathophysiological events in the early phase of meningococcal shock. Support for 
these theories is found in our observation that in patients with less complement 
activation, intravascular neutrophil activation and endothelial damage, i.e. patients 
with meningitis without shock, the increment in the ratio TNFsR-p75 to TNFsR-p55 
was less pronounced. At last DXM, a well-known modulator of the cytokine network, 
may have influenced the observed pattern. However, as DXM was prescribed in 
similar dosages in 14 of the 15 non-shock patients and in 23 of the 24 shock 
patients, DXM cannot explain the difference between both groups.
The present study underscores the importance of the timing of blood sampling for 
TNF, as its plasma concentration normalizes very rapidly. TNFsRs in contrast, 
disappear more slowly and still differentiate between non-shock and shock when 
samples are drawn some days after admission. Thus, timing of blood sampling is 
less critical for TNFsR measurements, and therefore TNFsRs are a better marker for
20 21 43the prognostic evaluation of cytokine mediated diseases ' . The different kinetic 
behaviour of TNF and its soluble receptors forms also an argument against the use 
of the ratio TNF to TNFsR as an indicator of pro-inflammatory disbalance6. 
Persistently elevated TNFsR plasma concentrations may be a reflection of impaired
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clearance or ongoing production. Several authors suggested that in sepsis, the
20 21 23 24increased TNFsR concentrations are a reflection of impaired renal clearance ’ ’ 
However, as we have shown, renal insufficiency is not the only explanation for the 
persistently elevated TNFsR levels, since renal function in non-shock and surviving 
shock patients both normalized within 2 days whereas TNFsRs remained elevated 
for 5 - 6 days.
Recently, we argued that PEBE will be able to accelarate the decrease of a 
circulating mediator only when the endogenous clearance of that mediator is low, i.e. 
when its half-life is long44. The overall half-life of both TNFsRs in the present study 
was 2 - 3 days and, as to be expected, PEBE clearly influenced the plasma pattern 
of these mediators. During PEBE sessions TNFsRs disappeared with half-lives of 
approximately 2.5 h (Table 2). However, after a PEBE session, a rebound of TNFsRs 
occurred. Due to this rebound, caused either by an increased release of TNFsRs 
from cell-membranes or by the delivery from other deep compartments, the overall 
effect of PEBE on the pattern of TNFsR was negligible. Probably, for a persistant 
effect a more frequent PEBE schedule would have been required.
In previous studies we showed that PEBE had only minor or no effect on the plasma 
pattern of TNF, IL-1IJ and IL-6, but that IL-1 soluble receptor type II and IL-6 soluble 
receptor were considerably affected28,44-46. In the present study we showed that 
PEBE influences the concentration of TNFsRs, but that this effect is only transient. 
Unfortunately, none of these observational studies allow conclusions on the clinical 
effect of PEBE. However, taken together these results show that the kinetic 
behaviour of various cytokines and their their soluble receptors differ importantly47. 
As a consequence, PEBE has a complex impact on the cytokine network. The 
biological effects of this impact are still unsolved.
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Cytokine induction by bacteria
A b str ac t .
The in-vitro production of interleukin-1 ß (IL-1ß), interleukin-6  (IL-6 ), and interleukin-1 - 
receptor-antagonist (IL-1 ra) in whole blood upon stimulation with different bacterial 
strains was measured to study the possible relationship between disease severity 
and cytokine inducing capacity of these strains.
Escherichia coli, Neisseria meningitidis, Neisseria gonorrhoeae, Bacteroides fragilis, 
Capnocytophaga canimorsus, Staphylococcus aureus, Enterococcus faecalis, 
Streptococcus pneumoniae, and Streptococcus pyogenes, induced the cytokines IL- 
1ß, IL-6  and IL-1 ra. Gram-negative bacteria induced significantly higher pro- 
inflammatory cytokine production than Gram-positive bacteria. These differences 
were less pronounced for the anti-inflamatory cytokine IL-1 ra.
In addition, blood was stimulated with Escherichia coli (E. coli) killed by different 
antibiotics to study the effect of the antibiotics on cytokine inducing capacity of the 
bacterial culture.
E. coli treated with cefuroxime and gentamicin induced higher levels of IL-1 ß and IL-6  
production but levels of IL-1 ra production similar to that of heat killed E. coli. In 
contrast, ciprofloxacin- and imipenem/cilastatin-mediated killing showed a decreased 
or similar level of induction of cytokine production as compared to that by heat killed E. 
coli', polymyxin-B decreased the production of the cytokines.
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In tr o d uc tio n .
The introduction of potent antimicrobial agents has increased survival among 
patients with Gram negative sepsis but mortality still varies between 20-50% 
especially in patients with shock31. This high mortality may be explained by the 
reaction of the patient to cell wall components from bacteria, in particular 
lipopolysaccharide (LPS) which induces an uncontrolled inflammatory reaction 
resulting in tissue damage and organ failure. LPS is released by living and growing 
bacteria but killing of the bacteria by antimicrobial agents may additionally liberate 
LPS. This may lead to an initial deleterious effect of antibiotic treatment on the 
condition of the patient. Such phenomena have been described for typhoid fever4 
and for suspected Gram negative sepsis33 and are supported by studies which show 
increased concentrations of LPS upon antibiotic treatment of clinical22 or 
experimental infections18’26'27,34, and in in-vitro models3'5'7,13,14,25’36.
The amount of LPS released is determined by the type and concentration of the 
antimicrobial agent as well as the nature and sensitivity of the bacteria. Plasma LPS 
concentrations usually do not correlate with clinical symptoms32. It is the induction of 
cytokines through cellwall components like LPS which are the mediators of biological 
responses during bacterial infections. Cytokines have repeatedly shown to correlate 
with clinical outcome8,10,19. The key-role of cytokines is also demonstrated by the 
capability of anti-tumor necrosis factor antibodies to prevent the Jarisch Herxheimer 
reaction when given before antibiotic treatment15. LPS is only one of the bacterial 
cellwall components that can induce an inflammatory response12. Gram positive 
microorganisms, which lack LPS in their cell wall, induce the release of cytokines by 
peptidoglycans and teichoic acid24,35.
We studied the relationship between the capacity of morphologically intact bacteria 
to induce cytokines in whole blood and clinical severity. In addition we studied the 
effect on cytokine induction by E. coli treated with a panel of different antibiotics.
The following mediators, which have been shown to correlate with disease severity 
and patient outcome, were measured: interleukin-1 p (IL-1R), interleukin-6  (IL-6 ), and 
the anti-inflammatory cytokine interleukin-1 receptor antagonist (IL-1 ra).
Materials  and  methods
The following micro-organisms were studied: Escherichia coli (ATCC 25922), 
Bacteroides fragilis (ATCC 10584), Staphylococcus aureus (ATCC 25293), 
Enterococcus faecalis (ATCC 29212), Streptococcus pneumoniae (ATCC 6305), 
Streptococcus pyogenes (ATCC 43202) and clinical isolates of Neisseria 
meningitidis, Neisseria gonorrhoeae, and Capnocytophaga canimorsus. Bacteria 
were cultured in Brain Heart Infusion broth. The number of bacteria were adjusted to 
the required turbidity by measuring the optical density. After dilution the bacteria 
were killed by X-ray irradiation at a dose of 25 kGy and added to whole human 
blood.
Whole blood stimulation: A modification of the method described by Desch et al.9 
was used. Whole blood was drawn from healthy hospital employees in a sterile
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vacuum tube (Sherwood Medical, Balleymoney, N. Ireland) to which sterile pyrogen 
free heparin (Organon Technika, Boxtel, The Netherlands) was added as 
anticoagulant at a final concentration of 50 lU/mL blood. Whole blood (0.5 mL) was 
added to a sterile polypropylene tube containing
10 pL stimulus or (as control) dilution buffer followed by incubation at 37 °C for 24 h. 
After incubation the tubes were centrifuged and plasma was collected and stored at - 
20 °C until used.
LPS from Escherichia coli serotype 055:B5 (Product No. L4005 Sigma, St Louis, Mo) 
at a final concentration of 10 pg/mL was used in each test as a reference for cytokine 
induction in the whole blood assay.
IL-6  ELISA was performed as described before19. In brief, a 96 well plate (Costar 
3500 EIA/RIA plate) was coated overnight at 4 °C with anti-IL-6  antibody (BE-8 ) and 
washed with washbuffer (phosphate buffer with 0.05% Tween 20). Wells were 
blocked with phosphate buffer containing 5% bovine serum albumin (BSA, Product 
No. A7030, Sigma) and after an hour at room temperature the plate was washed and 
samples or standard (recombinant IL-6 ) were added followed by an incubation of 1 h 
at 37 °C. Washing was repeated and a second biotinilated antibody to IL-6  was 
added. After 1 h incubation at room temperature the plate was washed and 
streptavidin-horse radish peroxidase (Product No. S5512, Sigma) was added to the 
wells for 45 minutes and subsequently washed. Thereafter O-phenyldiamine (0.5 
mg/mL Product No. P6912, Sigma) was added and after 15-20 minutes the color 
reaction was stopped with H2 SO4  (2.5 M). Optical density was read at 492 nm with 
an automated plate reader (Titertek Multiskan MCC/340, Labsystems, Amsterdam, 
The Netherlands). Detection limit of the assay was 20 pg/mL.
IL-1IJ , and IL-1ra were determined using radio-immuno-assays21,23. Recombinant 
human IL-1B , and IL-1 ra were used as standard. Detection limits of the assays 
varied between each run and were usually between 0.02 and 0.20 ng/mL.
LPS was detected with a chromogenic Limulus Amoebocyte Lysate assay (Coatest, 
Chromogenix, Molndal, Sweden) using the end-point method according to the 
instructions of the manufacturer. Detection limit of the assay was 12.5 pg/mL.
To investigate the effects of antibiotic treatment on the cytokine induction in whole 
blood,
E. coli (ATCC 25922) was cultured for 2Vz hours in TSB medium to induce 
logarithmic growth. Subsequently bacteria were cultured in broth at a concentration 
of 5x10® bacteria/mL in the presence of antibiotics for 24 hours. Heat killed E. coli 
showing morphologically intact micro-organisms on Gram stain were used as control. 
After incubation the antibiotic treated E. coli samples were tested in the whole blood 
assay. Final concentration in whole blood was 105 bacteria/mL.
Final concentrations of antibiotics used were as follows: ciprofloxacin 4 pg/mL 
(Bayer, Mijdrecht, The Netherlands); cefuroxime 80 pg/mL (Glaxo, Zeist, The 
Netherlands); gentamicin 10 pg/mL (Schering-Plough, The Netherlands); 
imipenem/cilastatin 50 pg/mL (Merck Sharp & Dohme, Haarlem, The Netherlands); 
and polymyxin-B 15 pg/mL (Pfizer, Capelle a/d IJssel, The Netherlands). These 
concentrations were based on the peak levels in human plasma during treatment
92
Chapter 7
with a standard intra-venous dosage. Antibiotic concentrations exceeded MICs >40 
times in all cases.
Statistical analysis. One way analysis of variance (ANOVA) was used for statistical 
analysis. Comparisons between bacteria and antibiotics were calculated using the 
Newman-Keuls test. A p-value <0.05 was considered statistically significant.
Results
Cytokine response to LPS in whole blood. Figure 1 shows the dose dependent 
increase in IL-1B and IL-6  concentrations upon addition of LPS to the whole blood 
system. A LPS concentration >0.1 ng/mL was required for the induction of IL-1B and 
IL-6 . The production of IL-16 in 3 donors induced by 10pg/mL LPS was 55.3 ± 20.0 
ng/mL, the IL-6  production was 26.8 ± 12.5 ng/mL (mean ± SD). In the absence of 
LPS there was some constitutive presence of IL-1ra of 1.2-3.6 ng/mL and no 
constitutive production of IL-1IS or IL-6  was detectable. Increase of IL-1ra production 
could already be achieved by 20 pg/mL LPS. Maximum IL-1ra production in whole 
blood was obtained with roughly 10,000-fold lower concentrations of LPS than the 
maximum IL-113. and IL-6  production. IL-1ra production induced by 10pg/mL LPS was 
12.6 ± 1.6 ng/mL (mean ± SD).
LPS (ng/mL)
Figure 1: Cytokine response (mean ±  SD) to different concentrations of LPS. Results 
are expressed as the percentage of response compared to 10 fjg/mL LPS.
IL-1fi: • , IL-6: m, lL-1ra: +.
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Cytokine induction by different bacteria. In figure 2 the results of IL-1 ft, IL-6  and IL- 
1ra production of 7 donors are shown as percentage from the stimulation with 10 
pg/mL LPS. Concentration of IL-6  induced by 10 pg/mL LPS was 84.2 ± 29.5 ng/mL, 
of IL-1 ft it was 35.7 ±11.6 ng/mL and of IL-1 ra: 11.9 ± 3.0 ng/mL (mean ± SD of 7 
donors). Cytokine induction by bacteria at a concentration of 0.5x10® colony forming 
units per mL (CFU/mL) could be detected for each bacterial species. The production 
of IL-6  and IL-1 ft was significantly higher in the presence of E. coii, N. meningitidis 
en N. gonorrhoeae, as compared to the Gram positive bacteria. Differences between 
these Gram negative bacteria and the Gram positive bacteria were also significant 
for IL-1 ra production but less pronounced. The Gram negative bacteria, Bacteroides 
fragilis and Capnocytophaga canimorsus, showed a capacity of inducing cytokines 
comparable to the Gram positive bacteria tested.
Induction of cytokines by antibiotic killed Escherichia coii. The cultures of E. coli were 
killed by the tested antibiotics within 1-18 hours. This was determined by 
subculturing. To ascertain that all bacteria were killed the experiments were 
performed after incubation of the cultures with the antibiotics for 24 hours.
At concentrations used in this study the antibiotics cefuroxime, gentamicin, 
ciprofloxacin and imipenem itself did not influence the LPS induced production of IL- 
1ft, IL-6  and IL-1 ra in whole blood. Polymyxin-B did significantly reduce the induction 
of cytokines by LPS (data not shown).
Table 1 shows the results of IL-6 , IL-1 ft and IL-1 ra induction by antibiotic killed E. 
coli. IL-1 ft production by the heat killed E. coli was 22.0 ± 13.9 ng/mL, IL-6  
production was 54.5 ± 31.6 ng/mL and IL-1 ra production was 14.8 ± 2.0 ng/mL 
(mean ± SD).
Table 1 : Cytokine induction by antibiotic killed E. coli
IL-1/? IL-6 IL-1ra
Cefuroxime 282.6 ± 28.4 % 177.4 + 46.3% 104.4 ± 9.2 %
Gentamicin 145.4 ±11.2 % 143.3 ± 32.0 % 114.9 ± 8.9%
Ciprofloxacin 86.8 ± 10.3% 88.9 ± 13.6% 108.8 ± 10.1 %
Imipenem 88.4 ± 40.1 % 87.5 ± 9.4 % 100.8 ± 6.4 %
Polymyxin-B 25.8 ± 4.2 % 14.6 ± 7.6 % 65.6 ± 20.7 %
ANOVA < 0.0001® 0.0002# 0.003*
Values are means ± SD of three tests. Values are expressed as percentage of induction 
compared to heat-killed E. coli.
® Newman-Keuls p < 0.05: all significantly different except ciproxin versus imipenem.
# Newman-Keuls p < 0.05: cefuroxime versus ciproxin and imipenem, and polymyxin-B 
versus all other antibiotics.
‘ Newman-Keuls: p < 0.05: polymyxin B versus all other antibiotics.
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Figure 2: IL-1ß, IL-6, and IL-1ra response of 7 donors (mean + SD) to Gram-negative 
and -positive bacteria at a concentration of 0.5x1 (P CFU/mL. Results are expressed as the 
percentage of response compared to 10 /tg/mL LPS.
IL-6 and IL-1 ß induction differed significantly between the antibiotics used. As 
compared to heat killed 105 CFU/mL E. coli, cefuroxime treated E. coli induced a 
significant increase in IL-6 and IL-1ß production. Gentamicin treatment also led to 
increased IL-1 ß and IL-6 induction although the increase of IL-6 was not significant. 
Ciprofloxacin and imipenem killed the bacteria without significantly increasing the
-------1
■ ■ ¡ ^ ■ 1 --------j
3-----------1
— i------ 1
]-------- 1
[ —..I-------1 IL-1ra
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induction of IL-6 and IL-1B. Treatment of E. coli with polymyxin-B resulted in a 
decrease of both IL-6 and IL-16 induction. IL-1ra production was little influenced by 
antibiotic killing except for polymyxin-B.
The production of IL1IJ by cefuroxime and polymyxin-B treated E. coli differed 
significantly from the production induced by the heat killed E. coli. Differences 
between antibiotics for induction of IL-1B production were significant for all antibiotics 
except imipenem versus ciprofloxacin. Differences between antibiotics of IL-6 
induction capacity were not significant for gentamicin versus ciprofloxacin, 
cefuroxime and imipenem and not for imipenem versus ciprofloxacin. For IL-1ra 
induction capacity only the differences of polymyxin-B versus heat killed E. coli and 
the other antibiotics were significant.
>* 20 
>  
o
CXM GM CIP IPM Poly-B
Figure 3: Limulus Amoebocyte Lysate activity increase in cultures of antibiotic killed 
Escherichia coli (1 (f CFU/mL). Results are expressed as the x-fold increase in Limulus 
Amoebocyte Lysate activity as compared to the same amount of heat killed E. coli. CXM = 
cefuroxime, GM = gentamicin, CIP = ciprofloxacin, IPM = imipenem/cilastatin, and Poly-B = 
polymyxin-B.
Effect of antibiotic treatment of Escherichia coli on the LPS concentration. Activity of 
the suspension of heat-killed E. coli in the Limulus Amoebocyte Lysate-assay (figure 
3) was lower as compared to the suspension of antibiotic treated E. coli (105 
CFU/mL). Cefuroxime treatment gave the highest increase of Limulus Amoebocyte
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Lysate-activity among the antibiotics tested. Gentamicin resulted in a lesser increase 
of Limulus Amoebocyte Lysate-activity compared to cefuroxime followed by 
ciprofloxacin and imipenem. Polymyxin-B treatment of E. coli resulted in hardly any 
increase in Limulus Amoebocyte Lysate-activity, however, polymyxin-B interferes in 
the Limulus Amoebocyte Lysate-assay.
In order to get an impression on the fraction of LPS that is bound to the bacteria and 
the fraction that is “free”, cultures were filtrated through a sterile pyrogen-free 40 
micron filter. Figure 3 shows the increase of Limulus Amoebocyte Lysate-activity as 
compared to the Limulus Amoebocyte Lysate-activity in the heat killed E. coli for both 
total and “free” LPS. The LPS concentration in the heat killed E. coli was 1.9 x 105 
pg/mL and after filtration it was 7.8 x 105 pg/mL. The fraction of “free” LPS was very 
low after cefuroxime and came into the range of the total amount of LPS in the other 
antibiotics, though it was still higher.
D iscussion
In this study we investigated the production of the pro-inflammatory cytokines IL-1IJ, 
IL-6 and the anti-inflammatory cytokine IL-1 ra in whole blood stimulated with a 
number of bacteria. Major differences were found between Gram negative and Gram 
positive bacteria in the induction of IL-1 fi, IL-6 and IL-1 ra production in whole blood. 
The higher production of cytokines induced by Gram negative bacteria might indicate 
that in Gram negative infections high cytokine induction leads to a more acute and 
fulminant clinical picture as compared to infections with Gram positive bacteria. 
Gram positive organisms though are capable of inducing cytokine production, but 
100 to 1000-fold more bacteria are needed to induce the same concentration of 
cytokines as Gram-negative bacteria. Thus, Gram negative organisms are more 
potent inducers of IL-1 li, IL-6 and IL-1 ra compared with Gram positive bacteria in the 
whole blood assay which confirms the studies with isolated monocytes performed by 
Timmerman and Mattson24,35.
The relation between the capacity to induce cytokine production in the whole blood 
assay and disease severity is less obvious for the individual bacterial strains. Gram 
negative sepsis with Neisseria meningitidis is a fulminant disease with high mortality 
which may be reflected by its capacity to induce a strong cytokine response in our in- 
vitro system. In contrast, Neisseria gonorrhoeae has similar induction capacity in our 
system but bacteremia with this micro-organism presents with mild clinical 
symptoms. Similarly Capnocytophaga canimorsus induces very low production of 
cytokines but can induce a very serious clinical picture of sepsis with high mortality2. 
The reason for this inconsistency might be the anatomical location of the infection 
(e.g. the central nervous system) or production of toxins (e.g. Capnocytophaga 
canimorsus™).
The differences in the mode of action of cefuroxime, gentamicin, ciprofloxacin and 
imipenem probably result in the differences in inducing cytokine production by 
treated E. coli. Imipenem makes the bacteria osmotic unstable and cefuroxime, also 
a li-lactam antibiotic, inhibits the formation of intercellular septa in dividing bacteria
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resulting in long filaments29. In the latter case one may assume that more cellwall 
components are formed. This is confirmed by the high IL-1R and IL-6 production. 
Dofferhof et al. also found that killing of E. coli by cefuroxime induced higher 
production of TNF in isolated monocytes compared to other antibiotics11. In their 
tests killing of £. coli with imipenem also resulted in the lowest induction of TNF and 
with cefuroxime the highest production was achieved. The LPS concentration found 
in the cultures with cefuroxime killed bacteria also indicate the formation of more cell 
wall mass. The large difference between total and “free” LPS with cefuroxime treated 
E. coli might indicate that most of the LPS is constituted in the filaments which might 
not pass through the filter.
Gentamicin (aminoglycoside) acts on protein synthesis while ciprofloxacin 
(fluoroquinolon) acts on DNA-gyrase, changing DNA-configuration. This might lead to 
a minimal change in production of cellwall components. In the study of Prins et al. 
gentamicin killing of E. coli results in less TNF production than when ciprofloxacin is 
used30. In our study the opposite is true for IL-1R and IL-6. Their explanation is the 
ability of aminoglycosides to bind and inactivate LPS1,17. Addition of LPS to whole 
blood in the presence of either gentamicin or ciprofloxacin, cefuroxime or imipenem 
did not influence cytokine production, leaving the methodological differences as 
possible explanation for this inconsistency. In our tests gentamicin might influence 
the structure of the cell wall in such a way that the cell wall components that are able 
to induce cytokine production become more available for cytokine producing cells. 
This is supported by the finding that the amount of LPS measured in the cultures 
was almost equal to that found in bacteria killed by imipenem or ciprofloxacin, 
although the induction of cytokine production by the latter two was much lower. 
Polymyxin-B acts in a completely different way. It kills the bacteria by changing the 
osmotic barrier. The major reason for the low induction of cytokines is the binding of 
polymyxin-B to LPS which results in a less biologically active form of the LPS6, as 
can be seen in our tests. This well known phenomenon does not only interfere with 
cytokine induction capacity but also disturbs the activity of LPS in the Limulus 
Amoebocyte Lysate-assay. Therefore no answer can be given on the question how 
much LPS can be found after killing of E. coli by polymyxin-B in this study.
Differences between antibiotics for the induction of the anti-inflammatory cytokine IL- 
1ra were not large, only polymyxin-B treated E. coli showed a lower induction of IL- 
1ra production. This probably results from the fact that IL-1ra production induced by 
LPS is about 10,000-fold more efficient than IL-1R production (see figure 1). With 
high concentrations of bacteria the production capacity of IL-1ra is already on a 
plateau and neither an increase nor a small decrease of cytokine inducing 
components can result in a change in IL-1 ra production. At lower concentrations of 
treated £. coli (2x103 CFU/mL) the production of IL-1ra shows a similar pattern as IL- 
1B and IL-6 (data not shown).
The modified ex-vivo cytokine production model that is used here is a good model to 
compare multiple stimuli. Other models that have been described used larger 
volumes of blood which limits the amount of stimuli which can be tested in one 
experiment28. Also blood diluted with medium is used but this changes the cellular
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environment. Here we showed that a small volume of blood (0.5 mL) can sufficiently 
produce the cytokines IL-1B, IL-6, and IL-1 ra when stimulated. The used anti­
coagulant also influences the cytokine production. Maximum cytokine production was 
achieved by the use of endotoxin-free heparin (data not shown).
The results of this study are in agreement with findings by others with respect to LPS 
release by antibiotic killed bacteria11'30,37. However, this study shows that there is a 
discrepancy between concentrations of LPS as measured in the Limulus 
Amoebocyte Lysate-assay and the induction of cytokines in whole blood. 
Components other than LPS, such as other cytokine inducing products derived from 
killed bacteria or even the drugs administered, could be responsible for this 
discrepancy. Clinical studies in humans should be done to see whether the 
differences between antibiotics seen in whole blood are clinically relevant. Since the 
differences between the induction of cytokines by different bacteria in whole blood 
can not always predict disease severity, clinical studies seem to be even more 
essential.
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Chapter 8
Cytokines are (anti-)inflammatory mediators in the host response to severe infections. These 
mediators as well as their soluble receptors can be found in the circulation. The cytokines 
interleukin-6 (IL-6) and tumor necrosis factor-a (TNF-a) have been extensively studied in 
severe infections. The role of soluble receptors of both cytokines in infectious diseases and 
their relation to their subsequent ligands remains to be determined, particularly in the case of 
IL-6. In this thesis IL-6, TNF-a and their soluble receptors are studied in-vivo and in-vitro, in 
health and during severe infections.
CHAPTER 1 concisely introduces IL-6, TNF, their soluble receptors, and their roles in 
immunomodulation and pathology, with the emphasis on infections. The importance to study 
the behaviour of soluble receptors under pathological conditions is underlined. The main 
reason is that the circulating receptors influence the biological activity of the respective 
cytokines and therefore might affect the outcome of disease.
At the time of the start of our studies, assays for IL-6, TNF-a and the soluble TNF receptors 
p55 and p75 were available and reference concentrations in different human body fluids had 
been described. Plasma concentrations of IL-6 are <20 pg/ml and TNF-a <5 pg/ml. The 
soluble TNF-receptors p55 and p75 are found in plasma at concentrations around 1 and 1.5 
ng/ml respectively. For the gp80 fragment of the soluble IL-6 receptor (slL-6R) no reference 
levels were available. CHAPTER 2 describes the assay for the gp80 fragment of the slL-6R. 
We measured the slL-6R concentration in biological fluids from non-pathological origin. 
Blood and urine were obtained from healthy volunteers. Cerebrospinal fluid (CSF) and 
synovial fluid (SF) were obtained from patients during spinal puncture and arthroscopy, 
respectively. Only CSF and SF of patients with proven non-pathological conditions were 
used in this study.
Baseline levels for slL-6R were 76.6 ± 19.3 ng/ml in serum and 3.7 ±1.3 ng/ml in urine. 
Concentrations in CSF and SF were 1.6 ± 0.4 ng/ml and 11.6 ± 3.3 ng/ml, respectively. IL-6 
concentrations were all below the detection limit (<20 pg/ml) in these fluids. Thus, slL-6R is 
detectable in serum, urine, CSF and SF during non-pathological conditions. The slL-6R 
concentrations in serum outrange levels in the other body fluids.
Studies on soluble TNF receptors had indicated a significant influence of the renal function 
on the circulating concentrations, both in patients with chronic renal failure and in sepsis- 
patients. Renal failure is often a complicating factor in severe infections. We therefore 
studied whether the SIL-6R would be affected similarly.
The concentrations of the slL-6R gp80 and soluble-gp130 (the soluble form of the signal 
transducing part of the IL-6 receptor), were measured in patients with different degrees of 
chronic renal failure (CHAPTER 3). Since one could speculate that renal replacement 
therapy would influence the concentrations, blood was also analyzed at different time points 
before and after dialysis.
The serum concentrations of the IL-6 receptors gp80 and gp130 were compared to those of 
the TNF receptors p55 and p75 in patients with end stage chronic renal failure (CRF), in 
patients treated with continuous ambulatory peritoneal dialysis (CAPD), and in patients 
treated with hemodialysis (HD). In healthy controls the concentrations of gp80, gp130, p55
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and p75 in serum were 82.1 ± 24.3, 87.9 ± 20.2, 1.1 ± 0.2, and 1.7 ± 0.3 ng/ml, respectively. 
These concentrations were significantly increased in CRF, in CAPD, and in HD (before 
dialysis session) although there was not a clear pattern between these patient groups. 
Hemodialysis did not result in a consistent change in serum concentrations of the various 
receptors.
The increase of the soluble IL-6 receptors (gp80 and gp130) in chronic renal failure is 
relatively low compared to the TNF receptors in this situation.
The cytokines IL-6 and TNF-a are elevated in severe infections such as sepsis-syndrome 
and meningococcal disease. To study the effects of elevated concentrations of IL-6 and TNF- 
a on their subsequent receptors, we collected sequentially plasma samples from such 
patients. Since cytokines bind to their (soluble) receptors an influence of the ligand on the 
concentration of its receptor can be expected. We therefore determined the cytokines and 
their respective receptors in patients with severe infections. IL-6 concentrations in the acute 
phase show a correlation with disease severity and outcome. In order to investigate if this 
would also be true for its soluble receptor gp80 we studied the patterns of slL-6R in these 
patients during the acute phase of sepsis and in meningococcal infection.
CHAPTER 4: Blood samples of septic patients were collected sequentially during a 7 hour 
time period. Serum IL-6 concentrations ranged between 34 and 763,000 pg/ml. 
Concentrations of IL-6 in non-survivors were higher than those in survivors but this was not 
statistically significant. The median slL-6R concentration in septic patients was 43 ng/ml, 
which was significantly lower than that observed in 19 healthy volunteers (80 ng/ml). slL-6R 
concentrations in survivors did not significantly differ from those in non-survivors. A negative 
correla-tion existed between IL-6 and slL-6R concentrations (r = -.72). No effect of moderate 
renal impairment was found on the slL-6R, contrary to the concentrations of p55 and p75 
which were significantly increased in patients with impaired renal function which corroborates 
the results described in chapter 3.
The negative correlation between the IL-6 and slL-6R concentrations suggests that IL-6 has 
a direct influence on its receptor. Studies in CHAPTER 5 were carried out to investigate sIL- 
6R patterns in the presence of both high (during the acute phase) and falling (during the 
recovery phase) concentrations of IL-6 during bacteriologically documented meningococcal 
infections.
Three groups of patients were identified; those with meningitis, those with meningitis and 
shock, and those with shock only. Part of the patients with shock underwent plasma or whole 
blood exchange, in order to accelerate the removal of endotoxin. Serum concentrations of IL-
6 and soluble IL-6 receptor were determined sequentially during the acute and recovery 
phase.
Peak levels of IL-6 were highest in the group of patients with shock only followed by the 
group of patients with both shock and meningitis and with meningitis. Soluble IL-6R 
concentrations showed the reverse pattern and were all below normal. Similar to the results 
in chapter 4, slL-6R concentrations correlated negatively with the IL-6 concentrations. During 
recovery IL-6 rapidly decreased and slL-6R levels increased transiently to supranormal
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values whereafter they returned to normal. Plasma or whole blood exchange did not 
significantly influence IL-6 concentrations. The slL-6R concentration, however, rose 
immediately after an exchange session and subsequently declined rapidly. Within this period, 
the rate of decline appeared to depend on the IL-6 concentration. If the IL-6 concentration 
was high slL-6R concentration declined faster than in the presence of low IL-6 
concentrations. The clinical relevance of this transient increase in slL-6R concentration 
needs to be determined.
The pattern of the slL-6R was completely different from the soluble TNF-receptors. 
Circulating levels of the latter were reported to be low under normal conditions and elevated 
under conditions where TNF is produced. The patterns of the soluble TNF-receptors were 
also analysed in the same group of patients with meningococcal infections (CHAPTER 6).
At admission patients with shock showed significantly higher TNF-a, p55 and p75 
concentrations than patients without shock. TNF concentrations normalized within 12-24 
hours. During the first 24 hours concentrations of the soluble receptors still differentiated 
between shock and nonshock. Patients with shock exhibited higher p75 to p55 ratio’s, 
indicating that in shock the increase in p75 exceeds that of p55. Plasma exchange or whole 
blood exchange accelerated the decrease of concentrations of soluble TNF receptors. 
However, because of a rebound after each exchange session, the overall half lives of both 
soluble receptors remained unaffected by the exchange procedure.
The studies described in chapter 5 and 6 thus demonstrate that the patterns of the soluble 
receptors for IL-6 and TNF are highly dependent on the concentration of their respective 
cytokines.
Bacteria and particularly cell wall components can induce the cytokines both in-vivo during 
severe infections and in vitro. The purpose of the in-vitro experiments in CHAPTER 7 was to 
study whether an association exists between the capacity of bacteria to induce cytokines and 
disease severity. Whole blood was incubated with Escherichia coli, Neisseria meningitidis, 
Neisseria gonorrhoeae, Bacteroides fragilis, Capnocytophaga canimorsus, Staphylococcus 
aureus, Enterococcus faecalis, Streptococcus pneumoniae, and Streptococcus pyogenes, 
and IL-1IJ, IL-6 and IL-1 receptor antagonist (IL-1 ra) were found in the plasma after the 
incubation period. No changes in the slL-6R concentration were found. Gram-negative 
bacteria induced significantly higher pro-inflammatory cytokine production than Gram- 
positive bacteria. These differences were less pronounced for the anti-inflammatory cytokine 
IL-1ra.
To study the effect of antibiotics on cytokine inducing capacity of the bacterial culture blood 
was stimulated with Escherichia coli (E. coli) killed by different antibiotics.
E. coli treated with cefuroxime and gentamicin induced a higher IL-1 fi and IL-6, but an 
unchanged IL-1ra production as compared to heat killed E. coli. In contrast, ciprofloxacin and 
imipenem/cilastatin mediated killing resulted in a decreased or similar induction of cytokine 
production as compared to heat killed E. coli; polymyxin-B decreased the production of the 
cytokines.
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These differences between antibiotics, observed in-vitro, may be important to consider when 
a choice has to be made between antibiotics of seemingly similar effectiveness. Patient 
studies need to confirm that the in-vitro results are also clinically relevant.
Future studies need to explore the correlation between cytokines and their receptors and 
disease severity and outcome. While correlations were sometimes found in our studies they 
do not prove a causal relationship. Intervention studies, either in animals or patients, might 
help in establishing such a relationship and clarify the physiological role of the soluble 
receptors. The apparent discrepancy between the positive effects reported in animal 
intervention studies with the soluble TNF receptors and the absence of an effect of such 
treatment in patients, underlines the difficulties which may be expected. It brings us back to 
the challenge of everyday clinical practice: the diversity of patients and diseases.
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Cytokines zijn eiwitten die een organisme produceert als reactie op onder andere een 
ernstige infectie. Deze mediatoren kunnen worden aangetoond in de circulatie maar hebben 
hun effecten met name in de vaatwand en op weefselniveau. Hoewel ze in essentie een 
positieve rol spelen in de afweer tegen infecties is het bekend dat een overdreven 
cytokinerespons ook een negatief effect kan hebben op het lichaam. In een dergelijk geval 
schiet de afweerreactie te ver door en kunnen onderscheiden organen in hun functioneren 
zodanig achteruit gaan dat de patiënt uiteindelijk zelfs kan overlijden. Ondanks het 
beschikbaar zijn van goede antibiotica, welke de bacteriën doden die de infectie 
veroorzaken, kan de lichaamseigen reactie er dus de oorzaak van zijn dat de patiënt in grote 
problemen komt. Het ziektebeeld met een ernstige infectie en zijn bijkomende complicaties 
wordt ook wel het sepsis-syndroom genoemd.
lnterleukine-6 (IL-6) en tumor necrosis factor (TNF) zijn cytokines, waarvan het beloop van 
de plasmaspiegels uitgebreid is bestudeerd in patiënten met ernstige infecties. Om hun 
effecten uit te oefenen moeten cytokines zich hechten aan een receptor op een lichaamscel. 
IL-6- en TNF-receptoren kunnen ook vrij in de circulatie voorkomen. Wanneer IL-6 of TNF 
zich bindt aan zijn circulerende (oplosbare) receptor heeft dit invloed op de biologische 
effektiviteit van het cytokine in de weefsels. Dit proefschrift beschrijft onderzoek naar de 
cytokines TNF en IL-6 en hun circulerende receptoren.
In h o o fd s tu k  1 worden de cytokines IL-6 en TNF en hun receptoren uitgebreid besproken. 
Er wordt ingegaan op wat er bekend is van hun rol ín en effecten óp de afweer en tijdens 
ziekteprocessen, en met name infecties. Het belang van onderzoek naar de rol die de 
circulerende cytokinereceptoren spelen wordt benadrukt. De voornaamste reden hiervoor is 
dat de receptoren de biologische aktiviteit van de cytokines sterk kunnen beïnvloeden en op 
die manier dus een rol spelen in het hele ziektebeloop.
Bij aanvang van onze studies waren reeds methodes beschikbaar om IL-6, TNF en de beide 
varianten van circulerende TNF-receptoren (p55 en p75) te meten. Ook was reeds bekend in 
welke concentraties deze voorkomen in bloed en in andere lichaamsvloeistoffen. Onder 
normale omstandigheden zijn IL-6- en TNF-concentraties in het bloed respectievelijk <20 
pg/ml en <5 pg/ml. De circulerende TNF-receptoren p55 en p75 komen voor in concentraties 
van respectievelijk 1 en 1,5 ng/ml. Voor de circulerende IL-6-receptor (gp80) was er nog 
geen meetmethode beschikbaar en derhalve ook nog geen normaalwaarde bij de mens.
Ho o fd s tu k  2 beschrijft de ontwikkeling van een dergelijke test, waarm ee vervolgens de 
gp80-concentratie gemeten is in lichaamsvloeistoffen van de mens. Bloed en urine werden 
afgenomen van gezonde vrijwilligers. Hersenvocht (liquor) en ook gewrichtsvloeistof 
(synoviaal vloeistof, SF) werd afgenomen bij patiënten die respectievelijk een ruggenprik of 
een kijkoperatie van de knie ondergingen. Alleen in die gevallen waarbij er geen afwijkingen 
werden gevonden bij het onderzoek werd de afgenomen vloeistof ook in de analyses 
gebruikt.
De normaalwaarden voor gp80 waren 76,6 ± 19,3 ng/ml in het bloed en 3,7 ±1,3 ng/ml in 
urine. Voor liquor was dit 1,6 ± 0,4 ng/ml en voor SF 11,6 ± 3,3 ng/ml. In geen van de 
afgenomen monsters kon IL-6 worden aangetoond. Onder normale omstandigheden komt
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gp80 dus in alle genoemde lichaamsvloeistoffen voor, waarbij de waarden in het bloed 
verreweg het hoogst zijn.
Studies betreffende de circulerende TNF-receptoren hadden reeds aangetoond dat de 
nierfunctie een grote invloed heeft op de concentraties van p55 en p75 in het bloed. Dit is 
beschreven in patiënten met chronisch nierfalen maar ook bij patiënten met het sepsis- 
syndroom die nierfalen ontwikkelen, h o o fd s tu k  3 beschrijft een studie naar het effect van 
nierfalen op de concentraties van gp80 in het bloed. Omdat het inmiddels mogelijk was 
geworden om ook de concentratie van het andere deel van de IL-6-receptor - gp130 - te 
meten, werd deze meegenomen in de analyses.
Bij patiënten in verschillende stadia van chronisch nierfalen werden de gp80- en gp130- 
concentraties, alsmede de TNF-receptoren p55 en p75 in het bloed gemeten. Omdat 
hemodialyse mogelijk eveneens een invloed kan hebben op de receptorconcentraties 
werden ook monsters vóór en na de hemodialysesessies verzameld. Gezonde vrijwilligers 
diende als controle. De concentraties in het bloed van deze laatste groep waren 82,1 ± 24,3 
ng/ml voor gp80, 87,9 ± 20,2 ng/ml voor gp130, 1,1 ±0,2 ng/ml voor p55 en 1,7 ± 0,3 ng/ml 
voor p75.
Deze concentraties waren significant verhoogd in zowel patiënten met ernstig nierfalen die 
nog net niet voor dialyse in aanmerking komen alsook in patiënten die dialyseren (CAPD of 
hemodialyse). Een consistent patroon was er echter tussen de onderscheiden receptoren in 
de verschillende patiëntengroepen niet te ontdekken. De relatieve toename in de 
concentraties van gp80 en gp130, ten opzichte van de gezonde vrijwilligers, onder invloed 
van een verminderde nierfunctie was relatief laag in vergelijking met de relatieve stijging van 
de TNF-receptoren. Hemodialyse had geen significant effect op de receptorconcentraties.
De concentraties van TNF en IL-6 in het bloed bij patiënten met een ernstige infectie zoals 
het sepsis-syndroom en meningococceninfectie zijn sterk verhoogd. Om te bestuderen of 
deze verhoogde cytokineconcentraties ook van invloed zijn op de concentratie van hun eigen 
circulerende receptoren hebben we van deze patiënten op gezette tijden bloedmonsters 
afgenomen. Omdat de betreffende cytokine zich niet alleen kan binden aan de celgebonden 
receptor maar ook aan de circulerende receptor kan men een beïnvloeding verwachten. 
Tevens is onderzocht of er een relatie bestaat tussen de hoogte van de receptorconcentratie 
en de ernst en het beloop van de infectie.
Gedurende een periode van 7 uur werden er bloedmonsters afgenomen van patiënten die 
leden aan het sepsis-syndroom (h o o fd s tu k  4). De concentratie IL-6 varieerde hierbij van 34 
tot 763.000 pg/ml. De IL-6-concentraties in de patiënten die overleden als gevolg van de 
sepsis waren hoger dan van degenen die wel overleefden, maar dit verschil was niet 
statistisch significant. De gp80-concentratie was 43 ng/ml (mediaan) hetgeen significant 
lager was dan in een controlegroep gezonde vrijwilligers (80 ng/ml). Er was geen significant 
verschil in gp80-concentratie tussen patiënten die wel en patiënten die niet overleefden. Er 
bestond een significante relatie tussen de IL-6- en de gp80-concentratie: hoe hoger de IL-6, 
des te lager de gp80 (r= -0,72.). Er was geen verschil in gp80-concentratie tussen patiënten
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met en zonder nierfunctiestoornissen. Een dergelijk verschil was wel aanwezig voor de p55- 
en p75-concentraties, hetgeen de bevindingen uit hoofdstuk 3 onderstreept.
De negatieve correlatie tussen IL-6 en gp80 deed vermoeden dat er een directe invloed 
bestond van IL-6 op de gp80-concentratie. De resultaten van de studies in h o o fd s tu k  5 
geven een beeld over de gp80-concentratie bij zowel een hoge IL-6-concentratie, in de acute 
fase van een meningococceninfectie, als bij een lage IL-6-concentratie, zoals deze gevonden 
wordt in de herstelfase van deze infectie.
Er zijn drie groepen te onderscheiden onder de patiënten met een meningococceninfectie: 
een groep met alleen meningitis, een groep met meningitis en septische shock, en een groep 
met alleen een septische shock. Een gedeelte van de patiënten met septische shock 
onderging plasma- of volbloed-wisseling met de bedoeling endotoxine, een bestanddeel van 
de bacteriewand, te verwijderen uit het bloed. De IL-6- en gp80-concentraties werden op 
gezette tijden in het bloed gemeten gedurende de acute- en de herstelfase.
De IL-6-concentratie was het hoogst in de patiënten met shock, gevolgd door de patiënten 
met meningitis en shock. De laagste IL-6-concentratie was te vinden bij de patiënten met 
alleen meningitis. De gp80-concentratie was in alle gevallen verlaagd en liet een precies 
tegenovergesteld verdelingspatroon over de drie groepen zien. Ook hier was er een 
negatieve correlatie tussen de IL-6- en gp80-concentraties.
In de herstelfase daalde de IL-6-concentratie snel maar de gp80-concentratie steeg gestaag 
naar een waarde die eerst boven normaal uitkwam maar daarna weer daalde tot normaal. 
Plasma- of volbloed-wisseling had geen significante invloed op de IL-6-concentratie. De 
gp80-concentratie steeg echter onmiddellijk na een wisseling maar daalde daarna ook weer 
snel terug naar ongeveer de waarde voor de wisseling. De snelheid waarmee die daling 
optrad was afhankelijk van de op dat moment aanwezige IL-6-concentratie. Was de IL-6- 
concentratie hoog dan daalde de gp80-concentratie snel en was de IL-6-concentratie laag 
dan daalde gp80 minder snel. Of dit effect ook klinische relevantie heeft moet verder 
uitgezocht worden.
De circulerende IL-6-receptor liet een geheel ander patroon zien dan de circulerende TNF- 
receptoren. Zoals eerder beschreven zijn deze laatste onder normale omstandigheden in 
lage concentraties aanwezig en onder omstandigheden met hoge TNF-concentraties gaat 
hun concentratie ook omhoog. In dezelfde groep patiënten met meningococceninfectie zijn 
ook TNF en de circulerende TNF-receptoren gemeten (h o o fd s tu k  6).
Bij opname in het ziekenhuis bleken de patiënten met shock een significant hogere TNF- 
concentratie te hebben dan de patiënten zonder shock. Deze concentratie normaliseerde 
zich binnen 12-24 uur. De TNF-receptor concentraties waren gedurende de eerste 24 uur 
ook hoger in de groepen met shock. De verhouding p75/p55 was ook hoger in de patiënten 
met shock hetgeen er op duidt dat er hier relatief meer p75 dan p55 vrijkomt. Plasma- of 
volbloed-wisseling gaf een kortstondige versnelling van de daling in TNF-receptor 
concentratie maar deze werd ook in dit geval snel tenietgedaan door een snelle terugkeer 
naar de uitgangswaarde vóór de wisseling.
De studies uit de hoofdstukken 5 en 6 laten zien dat de circulerende receptorconcentraties 
en hun concentratiebeloop onder sterke invloed staan van de cytokines IL-6 en TNF.
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Bacteriën en met name bestanddelen van de bacteriewand zijn in staat om de productie van 
cytokines te stimuleren. Dit gebeurt in vivo (in een levend organisme) maar is ook in het 
laboratorium na te bootsen (in vitro). De studies in h o o f d s t u k  7 hadden tot doel te 
onderzoeken of er een relatie bestaat tussen de cytokine-inducerende capaciteit van 
bacteriën en de ernst van de ziekte die ze veroorzaken.
Hiertoe werden aan volbloed de bacteriestammen Escherichia coli, Neisseria meningitidis, 
Neisseria gonorrhoeae, Bacteroides fragilis, Capnocytophaga canimorsus, Staphylococcus 
aureus, Enterococcus faecalis, Streptococcus pneumoniae of Streptococcus pyogenes 
toegevoegd en na een incubatieperiode een aantal cytokines gemeten. Na incubatie werd in 
het bloedplasma IL-1, IL-6 en IL-1 receptor-antagonist (IL-1ra) gevonden. Er werden geen 
veranderingen in de gp80-concentratie waargenomen. De Gram-negatieve bacteriën 
induceerden significant hogere concentraties van de ontstekings-bevorderende cytokines IL-
1 en IL-6 dan de Gram-positieve bacteriën. Het verschil tussen Gram-positief en Gram- 
negatief was duidelijk minder voor de ontstekingsremmende cytokine IL-1 ra.
Om te onderzoeken of het doden van de bacteriën door verschillende antibiotica effect heeft 
op de cytokine-inducerende capaciteit werd volbloed geïncubeerd met E. coli cultures die 
gedood waren door verschillende antibiotica en, ter vergelijking, met door hitte gedode E. coli 
bacteriën.
In vergelijking met de door hitte gedode bacteriën gaven de door cefuroxim en gentamicine 
gedode bacteriën een veel hogere IL-1 en IL-6 inductie, maar een zelfde IL-1 ra inductie. De 
door ciprofloxacine of imipenem/cilastatine gedode bacteriën lieten een verminderde of 
gelijke inductiecapaciteit zien vergeleken met de door hitte gedode bacteriën. Polymyxine-B 
remde de inductie van cytokines.
De verschillen tussen antibiotica die in deze in vitro experimenten werden gevonden kunnen 
ook van belang zijn bij het maken van een keuze tussen twee op zichzelf even effectieve 
antibiotica. Studies bij patiënten moeten echter nog aantonen of deze in vitro resultaten ook 
klinisch relevant zijn.
Verdere studies moeten gericht zijn op de relatie tussen de cytokines, hun receptoren en de 
ernst en afloop van de ziekte. Hoewel er in de beschreven studies soms correlaties zijn 
gevonden betekent dit niet automatisch dat er ook sprake is van een causaal verband. 
Interventie in de concentraties van de receptoren, bij proefdieren of patiënten, kunnen helpen 
om de onderlinge relaties te ontrafelen en de fysiologische rol van de cytokinereceptoren te 
verhelderen. De discrepantie die bij interventiestudies met de TNF-receptoren is gevonden 
tussen positief uitvallende dierproeven maar negatieve studies bij mensen geeft aan dat dit 
een moeizaam traject zal zijn. Immers, de klinische praktijk confronteert ons dagelijks met de 
diversiteit van patiënten en hun ziektes.
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Dankw o o rd
Als je zo lang aan een proefschrift hebt gewerkt als ik dan heb je of alles alleen 
moeten doen of heb je velen nodig gehad om je door alle dieptepunten heen te 
trekken. Dit laatste is hier het geval. Het is daarom moeilijk iedereen te bedanken die 
een bijdrage heeft geleverd aan de totstandkoming van dit proefschrift. Hier volgt 
toch een poging.
Allereerst diegenen die me in al die jaren hebben begeleid: Prof. Dr. Cees van der 
Linden, Robert Sauerwein en Thijs Hendriks. Vele uren aan besprekingen, turend 
naar de immer wisselende resultaten bij cellijnen hebben we doorgebracht. Talloze 
experimenten die uiteindelijk niet de juiste richting aangaven. Gelukkig waren er nog 
wel ‘leuke’ resultaten zodat er publikaties volgden. In mijn manuscripten werd dan 
vrolijk gestreept (“many cytoWnes are k n e w n maar ook dat is leren.
Zonder jullie overtuiging dat het verzamelde materiaal tot een proefschrift kon 
worden verwerkt was ik zelf niet op dat idee gekomen. Dat het na vele jaren er 
inderdaad van is gekomen is waarschijnlijk meer aan de inzet en telefoontjes van 
jullie te danken dan aan mijzelf. Bedankt voor het over de streep trekken!
De collega’s in de tijd waarin de experimenten zijn uitgevoerd ben ik ook zeer 
dankbaar. Voor hun adviezen, gezelligheid en kameraadschap. Ik heb er van 
genoten om met jullie op het lab bezig te zijn, nieuwe dingen te leren die vooral op 
handwerk aankwamen, het werd een soort hobby. Het was altijd weer een genot als 
een ELISA aan het eind van de dag inderdaad de verwachte kleurtjes liet zien, de 
teleurstelling des te groter als dat niet zo was. Monique, Ben, Arjan, Wilfried wil ik 
met name noemen en bedanken. Speciale dank voor Janet Mulder die heel veel 
experimenten voor en met mij heeft gedaan waaronder het experiment ‘in-een-half- 
uur-tijd-naar-Mc-Donalds-rijden-een-Big-Mac-menu-eten-met-chocolade-milkshake- 
en-dan-weer-gaan-werken’; dankjewel.
Heel veel anderen op allerlei laboratoria en afdelingen hebben ook bijgedragen aan 
dit proefschrift. Teveel namen om te noemen dus kan ik alleen maar zeggen: 
allemaal bedankt!.
En dan natuurlijk het thuisfront: Joyce en Laura. Vooral in de jaren dat er veel meer 
en belangrijker dingen (ja hoor, die zijn er echt!) in ons leven gebeurden dan het feit 
dat ik moest promoveren was het ook voor jullie moeilijk als ik toch weer verder ging 
met schrijven. Er moet nu een betere tijd aanbreken, met meer tijd voor elkaar. En 
Laura, maar goed dat je nog niet weet dat papa straks niet alleen maar dokter (je 
weet wel, die enge mannen in witte pakken) maar ook nog doctor is! Dames, 
bedankt!
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C urriculum  vitae
Johan Frieling, de auteur van dit proefschrift is op 17 maart 1967 geboren in Leuth, 
gemeente Ubbergen. Hij is getrouwd met Joyce en heeft één dochter, Laura.
Na zijn middelbare-school opleiding (ongedeeld V.W.O.) aan het Canisius College- 
Mater Dei te Nijmegen is hij in 1985 Geneeskunde gaan studeren aan de Katholieke 
Universiteit Nijmegen. Zijn interesse voor fundamentele wetenschap werd tijdens de 
wetenschappelijke stage bij de afdeling Radiodiagnostiek gewekt. In maart 1992 
werd de artsenbul behaald. In diezelfde maand startte hij als research fellow op de 
afdeling Heelkunde (hoofd: Prof. Dr. R.J.A. Goris) van het St. Radboudziekenhuis in 
Nijmegen. Onder leiding van Prof. Dr. C.J. van der Linden voerde hij voor de 
farmaceutische industrie klinisch geneesmiddelenonderzoek uit bij patiënten. Tevens 
werd in samenwerking met de afdeling Medische Microbiologie (hoofd: Prof. Dr. 
J.A.A. Hoogkamp-Korstanje) onder begeleiding van R.W. Sauerwein en T. Hendriks 
een aantal studies verricht die ten grondslag liggen aan dit proefschrift. In maart 
1995 is hij als Clinical Research Associate begonnen bij Bayer B.V. te Mijdrecht en 
daar sinds september 1997 werkzaam als Medical Adviser/Drug Safety Officer.
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